EUROPEAN HEMATOLOGY ASSOCIATION

19th Congress of EHA

 

12 - 15 June 2014 Milan
Close
N. Poster
Poster title
Applicant name
Status
  100-P NOVEL STAT5B MUTATIONS AS DRIVERS OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA Kontro Mika Received Received
  102-P LEAFING THROUGH THE GENOME OF B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA BY NEXT-GENERATION SEQUENCING TECHNOLOGIES Messina Monica Received Received
  103-P IMPACT OF VIRUSES ON THE PATHOGENESIS OF SPORADIC CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA: INTEGRATION AND PRESENCE OF 25.525 VIRAL GENOMES TESTED BY NEXT GENERATION SEQUENCING Fischer Ute Luigia Received Received
  104-P THE FIRST LNCRNA LANDSCAPE OF MAJOR GENETIC T-ALL SUBSETS AND GUILT-BY-ASSOCIATION ANALYSIS FOR ETP-ALL SPECIFIC LNCRNAS Wallaert Annelynn Luigia Received Received
  105-P PTEN MICRO-DELETIONS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ARE CAUSED BY ILLEGITIMATE RAG-MEDIATED RECOMBINATION EVENTS Mendes Rui Therese Received Received
  106-P CMYC-TRANSLOCATIONS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA la starza Roberta Received Received
  108-P RNA-SEQ ANALYSIS TO DISSECT THE BIOLOGY OF EARLY RESPONSE TO TREATMENT IN HIGH RISK VS. STANDARD RISK CHILDHOOD BCP-ALL PATIENTS Fazio Grazia Vu Received Received
  109-P DARATUMUMAB TREATMENT ALONE OR IN COMBINATION WITH VINCRISTINE RESULTS IN THE INHIBITION OF TUMOR GROWTH AND LONG TERM SURVIVAL IN PRECLINICAL MODELS OF ACUTE LYMPHOCYTIC LEUKEMIA Doshi Parul Giacoma Received Received
  110-P EVALUATION OF TP53 MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): RESULTS FROM IRON (INTERLABORATORY ROBUSTNESS OF NEXT-GENERATION SEQUENCING) II STUDY Brugnoletti Fulvia Ri Received Received
  111-P INVESTIGATION OF PH-LIKE ALL BY GENE SET ENRICHMENT ANALYSIS AND IDENTIFICATION OF THEIR SPECIFIC EXPRESSION GENES Iijima Kazutoshi Maria Received Received
  112-P ROLE OF THE HYSTONE DEACETYLASE INHIBITOR GIVINOSTAT (ITF2357) IN TREATMENT OF CRLF2 REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA savino Angela Maria Received Received
  113-P TELOMERE DNA CONTENT AND TP53 STATE PROVIDE AN INSIGHT INTO GENOMIC INSTABILITY IN OLDER ADULT PATIENTS WITH ALL Zakout Ghada Giacoma Received Received
  114-P FUNCTIONAL STUDIES OF IK6 EXPRESSION SHED LIGHT ON THE COOPERATING MECHANISMS UNDERLYING THE GAIN OF MALIGNANCY IN B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA zareian Nahid Giacoma Received Received
  115-P ETV6-RUNX1 DE-REGULATES THE CYTOSKELETON AND MIGRATION PROPERTIES OF B CELL PROGENITOR CELLS Palmi Chiara Giacoma Received Received
  116-P ECTOPIC EXPRESSION OF THE HEDGEHOG PATHWAY LIGANDS SHH AND IHH IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) Dagklis Antonis Giacoma Received Received
  117-P NON-INTENSIVE, BUT NO-INTERRUPTIONS PROTOCOL PROVIDES COMPARABLE RESULTS IN AYA AND OLDER ADULTS WITH PH-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA: THE RUSSIAN ACUTE LYMPHOBLASTIC LEUKEMIA (RALL) STUDY GR DROKOV Mikhail Giacoma Received Received
  119-P THE POOR PROGNOSTIC VALUE OF IKZF1-DELETION IN CHINESE ADULT COMMON B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND THE SUPERIORITY OF STEM CELL TRANSPLANTATION OVER CHEMOTHERAPY FOR IKZF1 DELETED PATIENTS Ruan Guo-Rui Chuan Received Received
  121-P COMPARISON OF BONE MARROW AND PERIPHERAL BLOOD SAMPLES FOR MINIMAL RESIDUAL DISEASE MONITORING IN INFANTS WITH MLL-REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA TREATED BY MLL-BABY PROTOCOL Tsaur Grigory WAGEN Received Received
  124-P NEGATIVE OUTCOME IN PTEN MUTATED ACUTE LYMPHOBLASTIC LEUKEMIA PEDIATRIC PATIENTS COULD BE MODULATED BY THE PRESENCE OF NOTCH1/FBXW7 MUTATIONS Vega-Garcia Nerea Tang Received Received
  128-P MLL REARRANGEMENT CONFERS THE POOREST PROGNOSIS AS THE SECOND MOST FREQUENT CHROMOSOME ABERRATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA, DATA FROM A SINGLE INSTITUTION IN CHINA ZHOU Hongsheng Anders Received Received
  130-P AML WITH EVI1 REARRANGEMENTS ARE CHARACTERIZED BY FREQUENT SF3B1 AND IKZF1 MUTATIONS Lavallée Vincent-Philippe Wah Received Received
  131-P SEQUENTIAL CARBOXY-TERMINAL PHOSPHORYLATION OF EVI1 UPON DNA DAMAGE Schneider Marion R. Received Received
  132-P SETBP1 MUTATIONS IN 106 PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASMS fabiani Emiliano Anders Received Received
  133-P FANCONI ANEMIA AND DNA-REPAIR GENE VARIANTS IN THERAPY-RELATED MYELOID NEOPLASMS fabiani Emiliano Anders Received Received
  135-P GENOMIC ANALYSIS OF THE CLONAL ORIGIN AND EVOLUTION OF ACUTE PROMYELOCYTIC LEUKEMIA IN A UNIQUE PATIENT WITH A VERY LATE (17 YEARS) RELAPSE zhang Xiaolu Wah Received Received
  136-P NOVEL MUTATED GENES IN ACUTE PROMYELOCYTIC LEUKEMIA IDENTIFIED BY WHOLE-EXOME SEQUENCING Ibañez Mariam Wah Received Received
  139-P IDENTIFICATION OF SOMATIC MUTATIONS OR FUSIONS BY RNA-SEQUENCING IN ACUTE MYELOID LEUKEMIA. Viganò Ilaria Anders Received Received
  141-P HALOPLEX TARGET DNA ENRICHMENT ALLOWS INVESTIGATION OF COPY NUMBER AND MUTATIONAL STATUS OF KEY GENES IN ACUTE MYELOID LEUKAEMIA WITH NORMAL KARYOTYPE Bolli Niccolo Received Received
  143-P THE CAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) OVEREXPRESSION INDUCES MYELOID TRANSFORMATION IN ZEBRAFISH Pigazzi Martina Anders Received Received
  144-P POTENT COOPERATION BETWEEN THE NUP98-NSD1 FUSION AND THE FLT3-ITD MUTATION IN ACUTE MYELOID LEUKAEMIA INDUCTION Thanasopoulou Angeliki Anders Received Received
  149-P SERIAL TRANSPLANTATION AND IN VIVO MONITORING OF PATIENT-DERIVED XENOGRAFTS: AN ADVANCED PRECLINICAL MODEL TO STUDY DIVERSE GENETIC AML SUBGROUPS IN MICE Vick Binje Anders Received Received
  151-P MESENCHYMAL STEM CELLS (MSCS) OF AML PATIENTS HARBOR CHROMOSOMAL DEFECTS DISTINCT FROM THOSE OF LEUKEMIC CELLS. Bernasconi Paolo R. Received Received
  152-P ALTERATIONS IN MESENCHYMAL STROMAL PRECURSOR CELLS FROM THE BONE MARROW OF THE ACUTE MYELOID LEUKEMIA PATIENTS: NEWLY DIAGNOSED, AND BEFORE AND AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Shipounova Irina Anders Received Received
  157-P LOW MST1 HIPPO KINASE EXPRESSION CONTRIBUTES TO DIFFERENTIATION DEFICIENCY IN AML CELLS Wampfler Julian Anders Received Received
  158-P NOVEL FUNCTION FOR THE RNA BINDING PROTEINS RBM38 AND DND1 IN AML CELL DIFFERENTIATION Wampfler Julian Anders Received Received
  159-P EARLY PERIPHERAL BLAST CELL CLEARANCE ASSESSED BY FLOW CYTOMETRY IN INDUCTION IS A NOVEL POWERFUL PROGNOSTIC INDICATOR IN ACUTE MYELOID LEUKEMIA: A NORTHERN ITALY LEUKEMIA GROUP (NILG) STUDY Mannelli Francesco Anders Received Received
  161-P PROGNOSTIC SIGNIFICANCE OF THE MRC CYTOGENETIC CLASSIFICATION COMPARED WITH THE EUROPEAN LEUKEMIANET (ELN) GENETIC RISK CLASSIFICATION SYSTEM IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) Kadia Tapan Received Received
  162-P WT1-ASSOCIATED MISSPLICING IN ACUTE MYELOID LEUKEMIA wattel Eric R. Received Received
  163-P VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION Yoon Jae-Ho Anders Received Received
  164-P WT1 MUTATIONS ARE SECONDARY EVENTS IN AML, SHOW VARYING FREQUENCIES WITHIN GENETIC SUBGROUPS AND DIFFERENT IMPACT ON PROGNOSIS Krauth Maria Wah Received Received
  166-P MULTICENTER SURVEY ON OUTCOME OF AML REFRACTORY TO FIRST INDUCTION CHEMOTHERAPY IN THE LAST 4 YEARS (2010-2013). Candoni Anna Received Received
  167-P PRETREATMENT RISK SCORE FOR PREDICTION OF EARLY DEATH AFTER INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELOID LEUKEMIA Djunic Irena Wah Received Received
  168-P TRAIL AND ITS RECEPTORS EXPRESSION ON LEUKEMIC CELLS OF PATIENTS WITH AML1-ETO POSITIVE ACUTE MYELOID LEUKEMIA Liu Li Gen Received Received
  170-P HIGH EXPRESSION LEVEL OF PRAME GENE IS FAVORABLE PROGNOSTIC FACTOR IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS Misyurin Vsevolod Gen Received Received
  171-P ASXL1 MUTATIONS DEFINE A SUBGROUP OF AML PATIENTS WITH DISTINCT GENE EXPRESSION PROFILE AND POOR PROGNOSIS: A META-ANALYSIS OF 3311 ADULT AML PATIENTS Shivarov Velizar Gen Received Received
  172-P INCIDENCE AND PROGNOSTIC IMPACT OF FLT3 AND NPM1 MUTATIONS IN ACUTE MYELOID LEUKEMIA AND CKIT AND NRAS GENE MUTATIONS IN RUNX1/RUNX1T1 AML Petrova Ekaterina R. Received Received
  175-P EARLY ABSOLUTE LYMPHOCYTE COUNT IS NOT A PREDICTOR OF RELAPSE OR SURVIVAL IN ACUTE MYELOID LEUKEMIA Yamazaki Etsuko R. Received Received
  176-P TREATMENT WITH RADIATION, CHEMOTHERAPY, OR BOTH DEMONSTRATES SIMILAR OUTCOMES IN PATIENTS WITH ISOLATED MYELOID SARCOMA THAT MAY NOT BE DIFFERENT THAN DE NOVO ACUTE MYELOID LEUKEMIA Feller Faye Gen Received Received
  177-P ACUTE MYELOID LEUKEMIA IN PATIENTS 70 AND ABOVE. AZACITIDINE VERSUS INTENSIVE CHEMOTHERAPY De La Fuente Received Received
  178-P LOW DOSE GEMTUZUMAB OZOGAMICIN PLUS FLAI AS INDUCTION THERAPY IN CD33-POSITIVE AML. DEFINITIVE RESULTS AND LONG TERM OUTCOME OF A PHASE III MULTICENTER PROSPECTIVE CLINICAL TRIAL (NCT.00909168). Candoni Anna Received Received
  182-P AZACITIDINE AND INTENSIVE CHEMOTHERAPY IN THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: A META-ANALYSIS Gao Sujun R. Received Received
  185-P PHASE I STUDY OF OPB-51602, AN INHIBITOR OF STAT3 PHOSPHORYLATION, IN PATIENTS WITH RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES TERUI Yasuhito Fuente Received Received
  189-P CHARACTERIZATION OF GLOBAL HYDROXYMETHYLATION LEVELS IN AML Kroeze Leonie Fuente Received Received
  194-P VARIABLE REACTIVE OXYGEN SPECIES LEVELS ARE ASSOCIATED WITH ANERGY IN CLL Linley Adam Fuente Received Received
  196-P MONOCYTE/MACROPHAGE LINEAGE CELLS SIGNIFICANTLY INFLUENCE THE SURVIVAL AND PROLIFERATION OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS Bertilaccio Maria Teresa Received Received
  198-P LENALIDOMIDE INDUCES A PRO-INFLAMMATORY PHENOTYPE IN NURSE-LIKE CELLS DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA Fiorcari Stefania Teresa Received Received
  200-P DIFFERENT CLL STEREOTYPED SUBSETS, VARYING TELOMERE LENGTHS: A MEASURE OF DISTINCT PROLIFERATIVE HISTORIES LINKED WITH UNIQUE CLINICOBIOLOGICAL FEATURES Stamatopoulos Kostas R. Received Received
  201-P SKEWING OF THE T-CELL RECEPTOR REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: WHAT LIES BENEATH? Vardi Anna Teresa Received Received
  203-P INTRA-PATIENT CLONAL AND SUBCLONAL HETEROGENEITY OF CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCES FROM CIRCULATING AND LYMPH NODAL COMPARTMENTS Del Giudice Ilaria Received Received
  204-P OVERCOMING RESISTANCE TO THE NOVEL BH3-MIMETIC ABT-199 IN A CLL LYMPH NODE MODEL; THE ROLE OF ABL AND BTK thijssen Rachel Ilaria Received Received
  206-P IMMUNOHISTOCHEMICAL ANALYSIS OF IL-6, IL-8/CXCR2 AXIS, TYROSINE P-STAT–3 AND SOCS-3 IN CLL LYMPH NODES: CORRELATION WITH MICROVASCULAR CHARACTERISTICS, CLINICAL FEATURES AND PROGNOSIS Sachanas Sotirios Ilaria Received Received
  207-P EXPRESSION AND FUNCTIONAL ACTIVITY OF THE TNFR-SUPERFAMILY MEMBER DEATH RECEPTOR 3 IN CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS ACTIVATED BY THE BCR Cavallini Chiara Ilaria Received Received
  208-P VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INCREASES CELL MIGRATION THROUGH INTERACTION WITH THE CXCR4/SDF1 AXIS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) Ballester Garcia Sandra Received Received
  209-P ANALYSIS OF IMMUNOGLOBULIN GENE REARRANGEMENTS IN CHINESE AND ITALIAN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Marinelli Marilisa Sandra Received Received
  211-P SRC INHIBITORS DOWNREGULATE CD20 AND MODULATE THE ACTIVITY OF THE CD20 PROMOTER Winiarska Magdalena R. Received Received
  212-P COMPLEX ACTIVATION OF ANGIOGENIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA: EVIDENCE FROM CIRCULATING ANGIOGENIC CYTOKINES. Smolej Lukas Sandra Received Received
  213-P CHRONIC LYMPHOCYTIC LEUKEMIA CELL CAPACITY OF EXPRESSING AND RESPONDING TO SURFACE IGM (S-IGM) OR S-IGD PREDICTS DISEASE PROGRESSION AND IS ASSOCIATED WITH SPECIFIC MIRNA/MRNA SIGNATURES Recchia Anna Grazia Received Received
  214-P B-CELL RECEPTOR SIGNALLING ENHANCES GLYCOLYSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA Valle Argos Beatriz Received Received
  215-P NICHEFORMING STROMAL ELEMENTS OF BONE MARROW AND LYMPH NODES IN CLL Semenova Natalya Beatriz Received Received
  216-P DISTRIBUTION OF CIRCULATING RESIDUAL NORMAL B-CELLS AND OTHER IMMUNE CELLS IN ADVANCED-STAGE B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ACCORDING TO THE NUMBER OF PRIOR TREATMENT LINES RECEIVED Barrena Susana Received Received
  217-P THE INFLUENCE OF BENDAMUSTINE USED ALONE OR IN COMBINATION WITH RITUXIMAB ON APOPTOSIS AND THE EXPRESSION OF SOME APOPTOSIS-REGULATING PROTEINS DEPENDING ON THE IGVH MUTATIONAL STATUS OF CLL CELLS Korycka-Wolowiec Anna Received Received
  218-P DECREASED DKK-1 LEVELS IN CHRONIC LYMPHOCYTIC LEUKEMIA AT INITIAL DIAGNOSIS MIGHT BE PREDICTIVE OF A HIGHER MORTALITY Pamuk Gulsum R. Received Received
  219-P MRD ANALYSIS IN BONE MARROW ASPIRATE AT 3 MONTHS AFTER TREATMENT IS THE OPTIMAL RESPONSE ASSESSMENT FOR CLL AND CAN PREDICT SUSTAINED MRD-NEGATIVE REMISSION INDEPENDENT OF ADVERSE PROGNOSTIC MARKERS Rawstron Andy Beatriz Received Received
  220-P NOT ALL IGHV3-21 CLL ARE EQUAL: SUBSET #2 DISPLAYS A DISTINCTIVE CLINICOBIOLOGICAL PROFILE WITH REMARKABLE SIMILARITIES TO SUBSET #169, ITS CLOSE IMMUNOGENETIC RELATIVE Baliakas Panagiotis Beatriz Received Received
  221-P IMMUNOGLOBULIN HEAVY VARIABLE GENES AND ALLELES: NEW ENTITIES, NEW NAMES AND IMPLICATIONS FOR RESEARCH AND PROGNOSTICATION IN CLL XOCHELLI Aliki Wah Received Received
  225-P THE DUAL PI3K/MTOR INHIBITOR PF-04691502 INDUCES SUBSTANTIAL APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDEPENDENTLY OF PROGNOSTIC MARKERS Blunt Matthew Beatriz Received Received
  226-P INDIRECT INDUCTION OF REGULATORY T CELLS ACCOMPANIES IMMUNE RESPONSES DURING VACCINATION OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH SHORT, RHAMM-DERIVED, MHC-I- RESTRICTED PEPTIDE Zaleska Joanna Beatriz Received Received
  228-P A B-CELL EPIGENETIC SIGNATURE DEFINES THREE BIOLOGICAL SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH MAJOR CLINICAL IMPACT Martin-Subero Jose I. Received Received
  232-P THE GENE EXPRESSION RESPONSE TO INTERLEUKIN-4 AND ITS DIFFERENTIAL MODULATION BY NFKB CORRELATE WITH ZAP70 IN CHRONIC LYMPHOCYTIC LEUKEMIA Parrado Antonio R. Received Received
  233-P ORAL FCR INDUCES HIGHER COMPLETE REMISSION RATES AND MRD NEGATIVITY IN UNTREATED CLL THAN PREVIOUS REPORTS OF INTRAVENOUS THERAPY: COMBINED RESULTS OF THE NCRI ADMIRE AND ARCTIC TRIALS Munir Talha R. Received Received
  234-P DEVELOPMENT AND VALIDATION OF COMPREHENSIVE CLL MUTATION DETECTION PANEL USING ION TORRENT NEXT GENERATION SEQUENCING PLATFORM Lozanski Gerard Wah Received Received
  238-P LATE ONSET NEUTROPENIA IS A COMMON COMPLICATION OF FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) THERAPY AND IS ASSOCIATED WITH SUBSTANTIAL MORBIDITY AND HOSPITALIZATION Ho Prahlad Wah Received Received
  240-P ?2-MICROGLOBULIN IS A DYNAMIC MARKER OF PROGNOSIS DURING TREATMENT OF CLL WITH FCR OR IBRUTINIB-BASED REGIMENS. Thompson Philip Beatriz Received Received
  241-P FIRST-LINE TREATMENT STRATEGIES FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY RESULTS OF A NETWORK META-ANALYSIS Rancea Michaela R. Received Received
  245-P A SYSTEMATIC REVIEW AND EVIDENCE SYNTHESIS OF RANDOMISED CONTROLLED TRIALS (RCT) FOR THE TREATMENT OF RELAPASED OR REFRACTORY CHRONIC LYMPHOCTYIC LEUKEMIA (CLL) Quigley Joan Beatriz Received Received
  246-P PROSPECTIVE VALIDATION OF A RISK SCORE BASED ON BIOLOGICAL MARKERS FOR PREDICTING PFS IN BINET STAGE A CLL PATIENTS: RESULTS OF THE MULTICENTER O-CLL1-GISL STUDY Gentile Massimo Beatriz Received Received
  247-P SALVAGE TREATMENT WITH BENDAMUSTINE, OFATUMUMAB, HIGH-DOSE METHYLPREDNISOLONE (BOMP) IN HIGH-RISK R/R CLL : INTERIM RESULTS OF THE FRENCH CLL INTERGROUP (GCFLLC/MW - GOELAMS) ICLL01 PHASE 2 TRIAL. Tournilhac Olivier Beatriz Received Received
  248-P NOVEL GENE MUTATIONS IN CHINESE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS xia Yi R. Received Received
  251-P THE ROLE OF ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RICHTER´S SYNDROME - META-ANALYSIS Antic Darko Beatriz Received Received
  253-P BLOOD STREAM INFECTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: STABLE DISTRIBUTION BUT WITH INCREASED MORTALITY RATE? Kjellander Christian Beatriz Received Received
  254-P TARGETING OF STAT3 AND STAT5 BY A NOVEL DRUG- COMBINATION EMPLOYING PONATINIB AND BARDOXOLONE METHYL (CDDO-ME) LEADS TO SYNERGISTIC EFFECTS IN BCR/ABL-T315I-MUTATED CELLS IN PH+ CML Gleixner Karoline Beatriz Received Received
  255-P CD62L EXPRESSION ON T CELLS IS DECREASED IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP) AND PREDICTS RESPONSE TO THERAPY WITH FRONTLINE NILOTINIB Sopper Sieghart Beatriz Received Received
  256-P LASP1 IS A NOVEL BCR-ABL SUBSTRATE AND A PHOSPHORYLATION-DEPENDENT BINDING PARTNER OF CRKL IN CHRONIC MYELOID LEUKEMIA Frietsch Jochen R. Received Received
  257-P DNA METHYLTRANSFERASE 1-DRIVEN HYPER-METHYLATION OF ? CATENIN ANTAGONIST CHIBBY1 IS NOT AN EPIGENETIC MARK OF CHRONIC MYELOID LEUKEMIA RESISTANCE TO IMATINIB Leo Elisa Beatriz Received Received
  258-P MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) AS POTENTIAL IMMUNE ESCAPE MECHANISM IN CML PATIENTS Giallongo Cesarina Beatriz Received Received
  259-P BIN1 AND RIN1 MODULATION IN CHRONIC MYELOID LEUKEMIA Trino Stefania Beatriz Received Received
  260-P PROMOTER METHYLATION OF THE TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN CHRONIC MYELOGENOUS LEUKEMIA MORI Naoki R. Received Received
  263-P IMPACT OF CLONAL EVOLUTION ON THE OVERALL SURVIVAL OF PATIENTS WITH CML TREATED WITH IMATINIB: EXPERIENCE OF ONE CENTER Kotlyarchuk Kostyantyn Beatriz Received Received
  264-P A FUNCTIONAL POLYMORPHISM IN THE 3´ UNTRANSLATED REGION OF THE ARHGAP26 GENE CONFERS AN INCREASED RISK OF CHRONIC MYELOID LEUKEMIA AND CAUSES ILLEGITIMATE REGULATION BY MICRORNA-18A-3P Dzikiewicz-Krawczyk Agnieszka R. Received Received
  266-P MUTATED SETBP1 INCREASES THE NUCLEAR LOCALIZATION OF PP2A AND ITS PHOSPHORYLATED FORM Redaelli Sara Beatriz Received Received
  268-P GENE EXPRESSION PROFILING OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT DIAGNOSIS IDENTIFIES NEW GENES RELATED TO THE NUMBER OF CD34+/LIN- CELLS DURING NILOTINIB TREATMENT Trojani Alessandra R. Received Received
  269-P EXPRESSION LEVELS OF CERAMIDE-GENERATING AND CLEARANCE GENES IN NEWLY DIAGNOSED AND TYROSINE KINASE INHIBITOR-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS: AN ATTEMPT TO FIND NOVEL TARGETS Kartal Yandim Melis Received Received
  270-P MIRNA-30E TARGETS BCR-ABL1 AND SENSITIZES K562 CELLS TO IMATINIB TREATMENT Granot Galit Beatriz Received Received
  271-P ANTILEUKEMIC EFFECT OF PLK INHIBITOR AND IN COMBINATION WITH ABL TYROSINE KINASE INHIBITORS AGAINST BCR-ABL-POSITIVE CELLS Okabe Seiichi Received Received
  273-P TYROSINE KINASE INHIBITORS DO NOT AFFECT EXPRESSION OF DNA METHYLTRANSFERASES AND GLOBAL METHYLATION LEVEL IN CHRONIC MYELOID LEUKEMIA CELLS Stoklosa Tomasz Beatriz Received Received
  276-P DECLINING ROLE OF DISEASE TRANSORMATION AS A CAUSE OF DEATH IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB IN EARLY CHRONIC PHASE: A LONG-TERM ANALYSIS BY THE GIMEMA CML WP Castagnetti Fausto Received Received
  277-P NEW MOLECULAR MARKERS OF CML PROGRESSION Misyurin Vsevolod Beatriz Received Received
  278-P PROGNOSIS FOR CML PATIENTS WITH >10% BCR-ABL AFTER 3 MONTHS OF IMATINIB DEPENDS ON THE INITIAL RATE OF BCR-ABL DECLINE Branford Susan Melis Received Received
  283-P AGE AND DIGITAL-PCR ANALYSIS PREDICT RELAPSES OF CML PATIENTS FOLLOWING PROGRAMMED IMATINIB INTERRUPTION IN Q-RT-PCR NEGATIVE CHRONIC MYELOID LEUKEMIA PATIENTS Mori Silvia Beatriz Received Received
  284-P EARLY RESPONSE OF RADOTINIB THERAPY MAY PREDICT LONG-TERM OUTCOMES IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO BCR-ABL1 TKIS: 24 MONTH UPDATE OF PHASE 2 TRIAL Kim Sung-Hyun Melis Received Received
  285-P MR4.5 AT POST-TRANSPLANT 3 MONTHS WAS A PREDICTIVE FACTOR FOR LONG-TERM OUTCOMES IN THE PATIENTS UNDERWENT ALLOGENEIC SCT IN CML CP Lee Sung-Eun Melis Received Received
  286-P MOLECULAR MONITORING USING PERIPHERAL BLOOD COMBINED WITH BONE MARROW AT 3 MONTHS OR 6 MONTHS PROVIDES A BETTER PREDICTOR OF OUTCOMES FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA Jiang Qian Melis Received Received
  287-P BCR-ABL1 RATIO LOG REDUCTION IS A BETTER PREDICTOR OF MAJOR MOLECULAR RESPONSE (MMR) THAN 10% RATIO CUT-OFF AT 3 MONTHS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS Del Orbe Rafael Received Received
  288-P GENEXPERT BCR-ABL1/ABL1 MONITOR TEST (IS) FOR ROUTINE MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS Balatzenko Gueorgui Beatriz Received Received
  290-P DISCONTINUATION OF IMATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE FOR AT LEAST 1 YEAR. OH Yunjeong Beatriz Received Received
  291-P CHANGES OF QUALITY OF LIFE AFTER CESSATION OF IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WITH UNDETECTABLE MOLECULAR RESIDUAL DISEASE Oh Sukjoong Rafael Received Received
  293-P LENALIDOMIDE MODIFIES THE BEHAVIOR OF MESENCHYMAL STROMAL CELLS (MSC) FROM PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH 5Q- (MDS-5Q-) Muntion Sandra Beatriz Received Received
  294-P IMPAIRED LINEAGE PRIMING AND PROLIFERATIVE POTENTIAL OF BONE MARROW MESENCHYMAL STEM CELLS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES ARE ASSOCIATED WITH ABNORMAL WNT SIGNALING PATHWAY Pontikoglou Charalampos Beatriz Received Received
  295-P INCREASED EXPRESSION OF INTERFERON RELATED GENES IN THE BONE MARROW MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES Kim Miyoung Beatriz Received Received
  297-P CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES. Zemanova Zuzana Beatriz Received Received
  300-P ANTI-ERYTHROBLAST AUTOIMMUNITY IN EARLY MYELODYSPLASTIC SYNDROMES: ENHANCEMENT OF EPO/EPO-R SYSTEM AND PRO-APOPTOTIC EFFECT zaninoni Anna Beatriz Received Received
  303-P DISTURBANCE OF EPIGENETIC STATUS IN STROMAL CELLS COULD BE INDUCED BY INTERACTION WITH MDS/AML-INITIATING CELLS. Kobune Masayoshi Wah Received Received
  304-P INDEPENDENT MULTICENTRIC STUDY ON THE INTEREST OF OGATA SCORE AND OF CD5, CD7 AND CD56 IN MDS AND MDS/MPS IN REAL LIFE. GUERIN Estelle Rafael Received Received
  305-P SELECTIVE EFFECT OF LENALIDOMIDE ON CELL CYCLE AND INOSITIDE-DEPENDENT ERYTHROID SIGNALLING IN DEL(5Q) CELLS AND MYELODYSPLASTIC SYNDROMES (MDS) Follo Matilde Y. Received Received
  306-P POSSIBLE PREVENTIVE ROLE OF CXCR4 AND ACTIVE CASPASE 3 IN LEUKEMIC EVOLUTION OF MYELODYSPLASTIC SYNDROMES Nikolova Veselka Y. Received Received
  307-P NEW GERMLINE TERT GENE MUTATIONS IN APLASTIC ANEMIA / HYPOCELLULAR MYELODYSPLASTIC SYNDROMES Matteucci Caterina Y. Received Received
  308-P IS THERE A RELATIONSHIP BETWEEN BONE MARROW CYTOMORPHOLOGY AND FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES? GUERIN Estelle Rafael Received Received
  309-P MOLECULAR CYTOGENETIC CHARACTERIZATION OF T(2;5)(P16.2;Q33.1) LEADING TO PDGFRB/SPTBN1 GENE FUSION IN A CASE OF MDS RESPONSIVE TO IMATINIB MESYLATE KOUMBI Daphne Y. Received Received
  310-P THE INTERPLAY BETWEEN OXIDATIVE STRESS AND EPIGENETIC PROFILE IN MYELOID NEOPLASIAS Gonçalves Ana Cristina Received Received
  311-P IMMUNE SURVEILLANCE IMPACTS PROGNOSIS: REGULATORY T CELLS AND PROGENITOR B CELLS ARE INDEPENDENT PREDICTORS OF SURVIVAL IN LOW AND INTERMEDIATE RISK MDS kahn Josephine Rafael Received Received
  312-P DEFERASIROX CHELATION THERAPY IN TRANSFUSION DEPENDENT MDS PATIENTS. A "REAL WORLD" REPORT FROM TWO REGIONAL ITALIAN REGISTRIES : GRUPPO ROMANO MIELODISPLASIE AND REGISTRO BASILICATA Maurillo Luca Cristina Received Received
  313-P THE INCIDENCE OF COMORBIDITIES AT THE TIME OF DIAGNOSIS IN PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES: OVERVIEW THROUGH THE "REL" ("RETE EMATOLOGICA LOMBARDA") DISEASE REGISTRY Riva Marta Rafael Received Received
  314-P MYOCARDIAL TISSUE CHARACTERIZATION BY CARDIAC MR IMAGING IN MYELODYSPLASTIC SYNDROMES Meloni Antonella Rafael Received Received
  315-P PRE AND POST-TREATMENT SERUM FERRITIN LEVELS IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES RECEIVING ERYTHROPOIESIS STIMULATING AGENTS Leitch Heather Rafael Received Received
  316-P VALIDATION OF LOW RISK PROGNOSTIC SCORING SYSTEM (LR-PSS) IN 318 PATIENTS WITH LOWER RISK IPSS MYELODYSPLASTIC SYNDROME FROM A SINGLE CENTER. POMARES MARIN Helena Received Received
  317-P MRI SURVEY IN TRANSFUSION-DEPENDENT AND NON-TRANSFUSION-DEPENDENT MDS PATIENTS Meloni Antonella Rafael Received Received
  318-P THE IMPACT OF TRANSFUSION DEPENDENCY ON THE OUTCOME OF PATIENTS WITH VERY LOW AND LOW RISK MYELODYSPLASTIC SYNDROME ACCORDING TO THE IPSS-R. Arnan Montse Cristina Received Received
  319-P CALRETICULIN MUTATION WAS RARELY DETECTED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME Hou Hsin-An Cristina Received Received
  323-P THE USE OF MEDICAL CLAIMS TO ASSESS INCIDENCE, DIAGNOSTIC PROCEDURES AND INITIAL TREATMENT AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE NETHERLANDS Dinmohamed Avinash Rafael Received Received
  325-P THE IMPORTANCE OF CYTOGENETIC SCORING SYSTEM IN MYELODYSPLASTIC SYNDROME Drevojankova Bronislava Rafael Received Received
  326-P DAPK AND TRAIL RECEPTORS METHYLATION STATUS IN MYELODYSPLASTIC SYNDROMES PATIENTS Gonçalves Ana Cristina Received Received
  327-P IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME Michele Cea Cristina Received Received
  328-P BONE MARROW CD14+ CELLS SHOW DIFFERENT TRANSCRIPTIONAL PROFILES IN MULTIPLE MYELOMA (MM) AS COMPARED TO SMOLDERING MM AND MGUS: OVEREXPRESSION OF IL-21R AND ITS INVOLVEMENT IN OSTEOCLASTOGENESIS. Giuliani Nicola Cristina Received Received
  329-P HOW DOES LENALIDOMIDE/DEXAMETHASONE REDUCES RISK OF TRANSFORMATION IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA? LONGITUDINAL IMMUNOPHENOTYPIC PROFILING OF IMMUNE EFFECTOR CELLS FROM THE QUIREDEX TRIAL Paiva Bruno Cristina Received Received
  330-P LONG-TERM RESULTS OF THE GIMEMA VEL-03-096 TRIAL IN MULTIPLE MYELOMA PATIENTS RECEIVING VTD CONSOLIDATION AFTER ASCT: IMPACT OF MRD KINETICS ON DURATION OF RESPONSE AND OVERALL SURVIVAL Ferrero Simone Cristina Received Received
  331-P THE EXPRESSION OF HIGH LEVELS OF CRBN ISOFORM LACKING IMIDS BINDING DOMAIN PREDICTS FOR A LOWER PROBABILITY OF HIGH-QUALITY RESPONSE TO IMID-BASED UPFRONT THERAPY IN NEWLY DIAGNOSED MYELOMA PATIENTS Terragna Carolina Cristina Received Received
  332-P ACTIVATED AND EXPANDED NATURAL KILLER (NKAE) CELLS KILL MULTIPLE MYELOMA (MM) CLONOGENIC PLASMA CELLS THROUGH NKG2D AND NKP30 RECEPTORS AND THEIR LIGANDS Leivas Alejandra Cristina Received Received
  333-P CIRCULATING MIR-34A AND MIR-130A AS BIOMARKERS OF EXTRAMEDULLARY DISEASE Kubiczkova Lenka Rafael Received Received
  335-P DOES CHARACTERISTIC PHENOTYPE FOR PLASMA CELL LEUKAEMIA EXIST? Rihova Lucie Cristina Received Received
  336-P GENE EXPRESSION PROFILING AND COPY NUMBER ALTERATIONS OF CIRCULATING CLONOTYPIC B CELLS OF MULTIPLE MYELOMA NEWLY DIAGNOSED PATIENTS REVEALS PATHWAYS POTENTIALLY INVOLVED IN THE DISEASE PERSISTENCE Martello Marina Cristina Received Received
  337-P CAN GENOME ARRAY SCREENING REPLACE FISH AS A FRONT-LINE TEST IN MULTIPLE MYELOMA? Gancheva Katya Cristina Received Received
  338-P COMPARATIVE STUDY OF GENE EXPRESSION PROFILING BETWEEN ASYMPTOMATIC AND SYMPTOMATIC WALDENSTRÖM´S MACROGLOBULINEMIA PATIENTS Jiménez Cristina Cristina Received Received
  339-P TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR FUNCTIONAL IMPACT IN MULTIPLE MYELOMA fulciniti Mariateresa Cristina Received Received
  340-P DOWNREGULATION OF TELOMERASE ACTIVITY IN RESPONSE TO NEW GENERATION OF PROTEASOME INHIBITORS (EPOXOMICIN AND MG132) IN MULTIPLE MYELOMA CELLS Muchtar Eli Helena Received Received
  341-P HSP90 INHIBITOR-DRUG CONJUGATES (HDC) WITH ANTITUMOR AGENTS TARGETING HEMATOLOGICAL MALIGNANCES Rao Patricia Received Received
  342-P TOLL-LIKE RECEPTOR ACTIVATION PROMOTES MULTIPLE MYELOMA CELL GROWTH AND SURVIVAL BY SUPPRESSION OF ENDOPLASMIC RETICULUM STRESS FACTOR CHOP BAGRATUNI Tina Cristina Received Received
  343-P ENDOPLASMIC RETICULUM STRESS-RELATED GENE EXPRESSION CAN PREDICT RESPONSE TO BORTEZOMIB IN MYELOMA Tomoko Narita Helena Received Received
  344-P MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS – TOWARDS PERSONALIZED MYELOMA THERAPY Gkotzamanidou Maria Rafael Received Received
  346-P TARGETING ANGIOGENESIS IN MULTIPLE MYELOMA: A POSSIBLE ROLE FOR EPHA3 AND A SPECIFIC MONOCLONAL ANTIBODY caivano Antonella Cristina Received Received
  348-P THE USE OF SINGLE AGENT ZOLEDRONIC ACID PREVENTS THE DEVELOPMENT OF BONE DISEASE COMPLICATIONS IN MYELOMA PATIENTS WITH ASYMPTOMATIC RELAPSES WITH NO DEMONSTRATED EFFECT ON SYMPTOMS PROGRESSION GARCIA-SANZ Ramon Helena Received Received
  349-P LENALIDOMIDE-DEXAMETHSONE (RD) VS MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) VS CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) IN ELDERLY COMMUNITY-BASED NEWLY DIAGNOSED MYELOMA PATIENTS Magarotto Valeria Cristina Received Received
  354-P GERIATRIC ASSESSMENT PREDICTS SURVIVAL AND RISK OF SERIOUS ADVERSE EVENTS FOR ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. Mina Roberto Cristina Received Received
  357-P EFFICACY AND SAFETY OF THREE SUBCUTANEOUS BORTEZOMIB COMBINATIONS IN ELDERLY, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS Cerrato Chiara Cristina Received Received
  358-P RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6 INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA Havens Tyce Cristina Received Received
  360-P PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM) Hansen Laura Cristina Received Received
  361-P POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) WITH DELETION DEL(17P) AND/OR TRANSLOCATION T(4;14). Leleu Xavier Rafael Received Received
  362-P PERSISTENT PFS BENEFIT AND SUPERIOR PFS2 WITH VTD VS TD FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MULTIPLE MYELOMA (MM) PATIENTS: UPDATED ANALYSIS OF GIMEMA MMY-3006 STUDY Pantani Lucia Cristina Received Received
  366-P OUTCOMES OF PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS IN PATIENTS TREATED UPFRONT WITH BORTEZOMIB OR LENALIDOMIDE AND THE IMPORTANCE OF RISK ADAPTED STRATEGIES Kastritis Efstathios Cristina Received Received
  370-P A PHASE 1 STUDY OF FILANESIB (ARRY-520) WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Walker Duncan Rafael Received Received
  374-P IDENTIFICATION OF REVERSIBLE RENAL DAMAGE AND EARLY MARKERS OF RESPONSE TO CHEMOTHERAPY IN AL AMYLOIDOSIS: A STUDY ON 732 PATIENTS Palladini Giovanni Cristina Received Received
  375-P MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) IS ASSOCIATED WITH A 30% INCREASED RISK OF DYING AT 8 YEARS OF FOLLOW-UP: RESULTS FROM A SCREENED CROSS-SECTIONAL POPULATION-BASED STUDY Lindqvist Ebba Cristina Received Received
  379-P BORTEZOMIB OR THALIDOMIDE INCORPORATED INTO AUTOLOGOUS STEM CELL TRANSPLANTATION VERSUS NOVEL AGENT-BASED TREATMENTS FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A CASE-MATCH COMPARISON tacchetti Paola Cristina Received Received
  380-P CAN 24-HOUR URINE COLLECTION BE REPLACED BY AN EARLY MORNING SAMPLE FOR BENCE JONES PROTEIN DETECTION AND QUANTIFICATION? Milani Paolo Cristina Received Received
  381-P PHASE II TRIAL OF LENALIDOMIDE, DEXAMETHASONE AND CYCLOPHOSPHAMIDE (LENDEXAL) FOR PREVIOUSLY UNTREATED PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS Cibeira M. Teresa Received Received
  382-P THE ADDITION OF BORTEZOMIB TO STANDARD MELPHALAN/DEXAMETHASONE IMPROVES THE QUALITY OF RESPONSE BUT DOES NOT REDUCE THE RATE OF EARLY DEATHS IN AL AMYLOIDOSIS: A MATCHED CASE CONTROL COMPARISON Palladini Giovanni Teresa Received Received
  384-P PLATELET MICROPARTICLE PROCOAGULANT AND PROANGIOGENIC FEATURES IN ESSENTIAL THROMBOCYTHEMIA (ET) Gamba Sara Teresa Received Received
  386-P MORGANA IS A NEW ONCOSUPPRESSOR IN CHRONIC MYELOID LEUKEMIA MOROTTI Alessandro Helena Received Received
  388-P INTRACELLULAR CALCIUM DEPOSITS AND STORE OPERATED CALCIUM ENTRY IN CD34+ CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING A CALR MUTATION Rosti Vittorio Teresa Received Received
  389-P VEGF-INDUCED CA2+ SIGNALS ARE DERANGED IN ENDOTHELIAL PROGENITOR CELLS FROM PATIENTS WITH MYELOFIBROSIS CARRYING JAK2 MUTATIONS Moccia Francesco Teresa Received Received
  392-P GATA1 IS OVEREXPRESSED IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND IT IS NORMALIZED BY ANAGRELIDE TREATMENT. RINALDI Ciro Helena Received Received
  393-P IMPORTANCE OF CALR MUTATIONS IN THE DIAGNOSIS OF PRIMARY MYELOFIBROSIS. Zamora Lurdes Teresa Received Received
  394-P THE SOMATIC MUTATION RATE IS INCREASED IN PATIENTS WITH CLASSICAL MYELOPROLIFERATIVE NEOPLASMS WHO HAVE A SECOND PRIMARY TUMOR. Notaro Rosario Teresa Received Received
  395-P MOUSE LEUKEMIC TRANSFORMATION IN PMF XENOGRAFT MODEL REVEALS PARACRINE REGULATION IN DISEASE PROGRESSION Triviai Ioanna Helena Received Received
  396-P CYTOGENETIC INVESTIGATION OF G-CSF-STIMULATED PERIPHERAL BLOOD IN PATIENTS WITH PRIMARY MYELOFIBROSIS Lozynskyy Rosyslav Teresa Received Received
  397-P CHARACTERIZATION OF MPL-MUTATED MYELOID NEOPLASMS: A REVIEW OF 224 MPL+ CASES Lin Keming Helena Received Received
  398-P DEREGULATION OF MICRORNA146B-1 IS ASSOCIATED WITH MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS Ha Jung Sook Received Received
  399-P HIGH THROUGHPUT SCREENING ON PERIFPERHAL BLOOD CD34 CELLS WITH A FLOW CYTOMETRY AUTOMATED PLATFORM (EXVITECH), TO IDENTIFY SENSITIVITY TO RUXOLITINIB IN MYELOFIBROSIS PATIENTS Arenas Alicia Teresa Received Received
  400-P HEMATOPOIETIC PROGENITOR CELLS EXPRESSING VE-CADHERIN ARE DETECTABLE IN THE SPLEEN OF PATIENTS WITH MYELOFIBROSIS AND ARE IN CLOSE CONTACT WITH MICROVESSELS Rosti Vittorio Teresa Received Received
  401-P EVALUATION OF THE ASSOCIATION BETWEEN JAK2 46/1 HAPLOTYPE AND MYELOPROLIFERATIVE NEOPLASMS Ha Jung Sook Received Received
  404-P OUTCOME OF JAK2/MPL/CALR TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION Panagiota Victoria Teresa Received Received
  406-P SURVIVAL IN PATIENTS WITH FAMILIAL AND SPORADIC MYELOPROLIFERATIVE NEOPLASMS Hultcrantz Malin Teresa Received Received
  408-P CLINICAL CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASM WITH CALRETICULIN MUTATIONS Krähling Tünde Teresa Received Received
  409-P JAK2 V617F ALLELE BURDEN AND VASCULAR COMPLICATION OCCURRENCE RISK IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS Borowczyk Martyna Received Received
  411-P UTILITY OF BONE MARROW HISTOLOGY AND IMMUNOHISTOCHEMISTRY IN THE DIAGNOSTIC WORK-UP OF EOSINOPHILIA OF UNKNOWN SIGNIFICANCE Metzgeroth Georgia Teresa Received Received
  412-P INFLUENCE OF IL-28B AND IL-6 GENETIC POLYMORPHISM ON IFN-ALFA TREATMENT OUTCOME IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL TROMBOCYTHEMIA Lindgren Marie Teresa Received Received
  413-P DYNAMICS OF CALR MUTANT ALLELE BURDEN IN ESSENTIAL THROMBOCYTHEMIA PATIENTS Bellosillo Beatriz Teresa Received Received
  415-P TREATMENT OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH PEGYLATED INTERFERON ALPHA-2A: A PROSPECTIVE MONOCENTER COHORT STUDY. De Stefano Valerio Received Received
  416-P SPECIFIC DETECTION OF CALR-MUTATED MYELOPROLIFERATIVE NEOPLASMS BY IMMUNOSTAINING Rotunno Giada Helena Received Received
  418-P MICROARRAY ANALYSIS OF CHROMOSOME 11Q IN A GROUP OF AGGRESSIVE LYMPHOMA: THE PARTIAL DUPLICATION OF 11Q AS A CYTOGENETIC MARKER OF SUBSET OF THE GREY ZONE BETWEEN BURKITT´S (BL) AND DIFFUSE LARGE B-C Grygalewicz Beata Helena Received Received
  419-P THE B CELL ANTIGEN RECEPTOR IS CRITICAL FOR BURKITT LYMPHOMA GROWTH VIA GSK3? REGULATION Varano Gabriele Valerio Received Received
  420-P CONCOMITANT INHIBITION OF EZH1 AND EZH2 IMPAIRS GROWTH OF C-MYC DRIVEN B CELL LYMPHOMAS Petrocelli Valentina Valerio Received Received
  422-P ACTIVATED SUMOYLATION MACHINERY IS A HALLMARK OF BURKITT LYMPHOMA WITH NEW THERAPEUTIC IMPLICATIONS Höllein Alexander Helena Received Received
  423-P CD19-TARGETING LIPOSOMES CONTAINING RAPAMYCIN INDUCE AUTOPHAGIC CELL DEATH IN BURKITT´S LYMPHOMA CELLS Sato Tsutomu Sook Received Received
  425-P HIGH EXPRESSION OF MIRNA-199A_1 AND MIRNA-497_1 IS ASSOCIATED WITH BETTER OVERALL SURVIVAL IN AGGRESSIVE NON-HODGKIN´S LYMPHOMA TROPPAN Katharina Sook Received Received
  429-P CONSTITUTIVE ACTIVATION OF THE DNA DAMAGE RESPONSE PATHWAY IS A NOVEL THERAPEUTIC TARGET IN DIFFUSE LARGE B-CELL LYMPHOMA. Derenzini Enrico Sook Received Received
  430-P FOXO1 TRANSCRIPTION FACTOR MEDIATES TOXICITY OF SYK INHIBITION IN DLBCL. Kiliszek Przemyslaw Sook Received Received
  431-P KINOME REPROGRAMMING IN DLBCL BY THE BTK-SPECIFIC INHIBITOR ONO-4059 HIGHLIGHTS SYNERGISTIC COMBINATIONS FOR CLINICAL APPLICATION Kozaki Ryohei Valerio Received Received
  432-P PRECLINICAL EVALUATION OF A NOVEL, HIGHLY POTENT AND SELECTIVE PI3K-DELTA INHIBITOR, CPL-302-201, FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES Stanczak Aleksandra Valerio Received Received
  435-P DIGITAL IMAGE ANALYSIS OF KI-67 FOR RISK STRATIFICATION OF PATIENTS WITH MANTLE CELL LYMPHOMA Blaker Yngvild Nuvin Received Received
  437-P ABSOLUTE MONOCYTE AND LYMPHOCYTE COUNT IN FOLLICULAR LYMPHOMA: PROGNOSTIC ROLE IN SURVIVAL OUTCOME EVALUATION SACCHI Stefano Nuvin Received Received
  438-P BRIEF RITUXIMAB, BENDAMUSTINE, MITOXANTRONE (R-BM) INDUCTION PLUS RITUXIMAB CONSOLIDATION IN ELDERLY DE NOVO ADVANCED STAGE FOLLICULAR LYMPHOMA: FINAL RESULTS OF A STUDY BY FONDAZIONE ITALIANA LINFOMI Boccomini Carola Valerio Received Received
  439-P BENDAMUSTINE IS NOT ASSOCIATED WITH AN INCREASE IN INFECTIONS – SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Gafter-Gvili Anat Helena Received Received
  440-P EXPRESSION OF CD200 AND CD148 IN LEUKEMIC B-CELL CHRONIC LYMPHOPROLIFERATIVE DISORDERS Fan Lei Valerio Received Received
  441-P ABEXINOSTAT (S78454) A HISTONE DEACETYLASE INHIBITOR, IN PATIENTS WITH REFRACTORY OR RELAPSED HODGKIN´S LYMPHOMA, NON-HODGKIN LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKAEMIA: PRELIMINARY PHASE II RESULTS. broussais Florence Nuvin Received Received
  442-P HIGH-DOSE CLARITHROMYCIN IS A FEASIBLE AND ACTIVE MONOTHERAPY FOR PATIENTS WITH RELAPSED/REFRACTORY EXTRANODAL MARGINAL ZONE LYMPHOMA [EMZL]: RESULTS FROM THE "HD-K" PHASE II TRIAL Ferreri Andres Valerio Received Received
  443-P EPIDEMIOLOGY OF NON-HODGKIN LYMPHOMA IN THE US: DISTRIBUTION BY SUBTYPES, DEMOGRAPHICS, AND TRENDS FROM 1998-2011 GO Ronald Nuvin Received Received
  446-P DROPLET PCR: A NEW SENSITIVE METHOD FOR DETECTING BRAFV600E MUTATION IN HAIRY CELL LEUKEMIA GALIMBERTI Sara Valerio Received Received
  448-P CLINICAL COMPARABILITY OF BCD-020 TO INNOVATOR RITUXIMAB IN PATIENTS WITH INDOLENT NON-HODGKIN´S LYMPHOMA Chernyaeva Ekaterina Nuvin Received Received
  449-P OCCURRENCE OF CHRONIC THERAPY-RELATED HYPOGAMMAGLOBULINAEMIA IN INDOLENT NON HODGKIN LYMPHOMA: SINGLE CENTRE EXPERIENCE. Pulsoni Alessandro Valerio Received Received
  450-P PERIPHERAL BLOOD LYMPHOCYTE/MONOCYTE RATIO (LMR) >2 IS ASSOCIATED WITH BETTER OUTCOME IN FOLLICULAR LYMPHOMA (FL): A SINGLE CENTRE EXPERIENCE Belotti Angelo Nuvin Received Received
  456-P PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA Wasserman Matthew Valerio Received Received
  457-P FREQUENCY OF SURVEILLANCE COMPUTED TOMOGRAPHY IN NON-HODGKIN LYMPHOMA AND THE RISK OF SECONDARY PRIMARY MALIGNANCIES Chien Sheng Hsuan Received Received
  459-P MYD88 (L265P) MUTATION IS AN INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA Fernandez Maria Concepción Received Received
  463-P APOPTOTIC POLYMORPHISMS ARE INVOLVED IN AGGRESSIVENESS AND PROGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA Borsarelli Carvalho Brito Received Received
  469-P EFFICALY OF M-NHL-BFM-90 TREATMENT PROTOCOL FOR PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA LUKINA Anna Helena Received Received
  471-P NON PEGILATED LIPOSOMAL DOXORUBICIN IS SAFE AND EFFECTIVE AS PART OF R-COMP IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND MODERATE/SEVERE HEART DISEASE. RESULTS OF HEART01 TRIAL BY THE FONDAZIONE Spina Michele Brito Received Received
  472-P HIGH DOSES OF ANTIMETABOLITES FOLLOWED BY HIGH-DOSE SEQUENTIAL CHEMOIMMUNOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANT IN SYSTEMIC B-CELL LYMPHOMAS WITH CNS INVOLVEMENT: A MULTICENTER PHASE II TRIAL Ferreri Andres Brito Received Received
  473-P R-ESHAP-LENALIDOMIDE AS SALVAGE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA CANDIDATES TO STEM-CELL TRANSPLANTATION: UPDATED RESULTS OF A PHASE IB GELTAMO STUDY REDONDO Alba Brito Received Received
  474-P NCCN-INTERNATIONAL PROGNOSTIC INDEX (NCCN-IPI) IS A POTENTIAL PROGNOSTIC MODEL IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA Xu Pengpeng Hsuan Received Received
  475-P RITUXIMAB-CHOP PLUS INTRATHECAL METHOTREXATE AND CONTRALATERAL TESTIS IRRADIATION IN UNTREATED PRIMARY TESTICULAR DIFFUSE LARGE B-CELL LYMPHOMA: LONG-TERM RESULTS OF THE IELSG-10 TRIAL Chiappella Annalisa Brito Received Received
  476-P THE NOVEL ROLE OF BONE MARROW INVOLVEMENT DETECTED BY BOTH STAGING AND INTERIM FDG PET-CT IN DIFFUSE LARGE B-CELL LYMPHOMAS Xu Wei Hsuan Received Received
  477-P MIR-155 IS ASSOCIATED WITH THE LEUKEMOGENIC POTENTIAL OF CLASS IV G-CSFR IN CD34+ PROGENITOR CELLS Figueiredo Constanca Hsuan Received Received
  478-P THE ROLE OF EPITHELIAL TO MESENCHYMAL TRANSITION IN THE REMODELING OF LUNG INJURY INDUCED BY ACUTE GRAFT-VERSUS-HOST DISEASE Liu Qifa Hsuan Received Received
  482-P RECIPIENT BATF3 DEPENDENT DENDRITIC CELLS SUPPRESS ACUTE GRAFT-VERSUS-HOST DISEASE AFTER EXPERIMENTAL ALLOGENEIC BONE MARROW TRANSPLANTATION Radsak Markus Hsuan Received Received
  483-P DISRUPTED TOLL-LIKE RECEPTOR SIGNALING OF INTESTINAL EPITHELIUM IN INTESTINAL GRAFT-VERSUS-HOST DISEASE Liu Qifa Hsuan Received Received
  484-P CYCLOSPORIN A DOES NOT IMPAIR EARLY GRANULOCYTE EFFECTOR FUNCTION Teschner Daniel Brito Received Received
  487-P ACTIVATED MONOCYTE-PHAGOCYTES PROBABLY INITIATE THE ONSET OF PRE-ENGRAFTMENT SYNDROME (PES) FOLLOWING UMBILICAL CORD BLOOD TRANSPLANTATION wang Jian Brito Received Received
  488-P INFLUENCE OF HLA-G POLYMORPHISM ON VIRAL REACTIVATION AND OVERALL SURVIVAL AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Metafuni Elisabetta Hsuan Received Received
  489-P MYELOID DERIVED SUPPRESSOR CELLS ARE MOBILIZED BY G-CSF IN MICE AND MEN WETZKO Katrin Hsuan Received Received
  490-P GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION AFFECTS THE EXPRESSION OF TH1/TH2 CHEMOKINES AND THEIR RECEPTORS Liu Qifa Hsuan Received Received
  491-P GRANULOCYTE COLONY-STIMULATING FACTOR MOBILIZATION AFFECTS THE EXPRESSION OF REGULATORY GAMMA DELTA T CELLS Liu Qifa Hsuan Received Received
  495-P ALDEHYDE DEHYDROGENASE-BRIGHT CELLS CORRELATED WITH THE COLONY FORMING UNIT-GRANULOCYTE/MACROPHAGE ASSAY OF THAWED CORD BLOOD UNITS Lee Hye Ryun Received Received
  496-P A MACHINE LEARNING BASED MODEL FOR PREDICTION OF NRM 100 DAYS POST ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT). A EUROPEAN REGISTRY DATA MINING STUDY. SHOUVAL Roni Ryun Received Received
  497-P CONTRASTING EFFECT OF MISSING SELF MODEL AND ACTIVATING DONOR KIR GENES WITH RELEVANT HLA LIGAND IN RECIPIENTS ON PREVENTING RELAPSE AFTER T-CELL-REPLETE HAPLOIDENTICAL TRANSPLANTATION IN CML Zhao Xiang-Yu Ryun Received Received
  498-P IMPACT OF SMOKING ON THE NON-RELAPSE MORTALITY, THE OVERALL SURVIVAL, AND THE INCIDENCE OF SECOND CANCERS AFTER REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES Spina Francesco Brito Received Received
  500-P IMPACT OF GRAFT SOURCE ON OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA. Nakajima Yuki Ryun Received Received
  501-P A POTENTIAL BENEFIT OF INHIBITORY KIR-MISMATCHED UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOLLOWING TBI-BASED CONDITIONING IN ADULT PATIENTS WITH AML Yahng Seung-Ah Brito Received Received
  506-P DECREASE OF INVASIVE FUNGAL DISEASE IN OUR CENTER WITH THE USE OF VORICONAZOLE AS ANTIFUNGAL PROPHYLAXIS IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION CHIC ACEVEDO Carolina Received Received
  507-P LONG-TERM SURVIVAL IN PATIENTS RECEIVING RHEPO FOLLOWING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION JASPERS Aurélie Carolina Received Received
  508-P SEQUENTIAL THIRD-PARTY MESENCHYMAL STROMAL CELL THERAPY FOR REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE Sanchez-Guijo Fermin Carolina Received Received
  509-P PLASMA PROHNPS ARE SPECIFIC EARLY MARKERS OF NEUTROPHIL ENGRAFTMENT IN PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY, AUTOLOGOUS OR ALLOGENEIC STEM CELL TRANSPLANTATION Glenthøj Andreas Ryun Received Received
  511-P HIGH-DOSE PREPARATION WITH THIOTEPA/ETOPOSIDE/ARA-C/MELPHALAN (TEAM) VS BEAM FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN LYMPHOMA: A RETROSPECTIVE STUDY FROM THE EBMT Dreger Peter Brito Received Received
  514-P THE IMPACT OF PRETRANSPLANT IRON CHELATING THERAPY WITH DEFERASIROX ON THE OUTCOME IN PATIENTS WITH SEVERE APASTIC ANEMIA UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION Lee Sung-Eun Ryun Received Received
  516-P THE RUNX-PU.1 PATHWAY PRESERVES NORMAL AND AML/ETO9A LEUKEMIC STEM CELLS Staber Philipp Brito Received Received
  517-P THE TISSUE INHIBITOR OF METALLOPROTEINASES-1 (TIMP-1) MODULATES HUMAN HSPC FUNCTIONS THROUGH CD63/PI3K/AKT SIGNALING Rossi Lara Carolina Received Received
  518-P LACK OF GLUCOCORTICOID-INDUCED LEUCINE ZIPPER (GILZ) RESULTS IN B CELL LYMPHOPROLIFERATIVE DISORDER IN MICE Bereshchenko Oxana Carolina Received Received
  524-P HISTONE DEACETYLACE INHIBITOR VORINOSTAT REDUCES KIT EXPRESSION BY DEREGULATION OF THE TRANSCRIPTIONAL COMPLEX AND INDUCTION OF HETEROCHROMATIN Abdulkadir Hani Carolina Received Received
  525-P ASSOCIATION OF AN IMPAIRED BONE MARROW VASCULAR MICROENVIRONMENT WITH PRIMARY FAILURE OF PLATELET ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Kong Yuan Ryun Received Received
  526-P REGULATION OF B LYMPHOPOIESIS BY SIGNAL-TRANSDUCING ADAPTOR PROTEIN-2, STAP-2 Ichii Michiko Received Received
  527-P IMPACT OF COLD SHOCK PROTEIN YBX1 ON HEMATOPOIETIC STEM CELL DEVELOPMENT AND FUNCTION Heidel Florian Ryun Received Received
  529-P IMMUNOMODULATION EFFECTS OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE Liu Qifa Ryun Received Received
  531-P MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES fabiani Emiliano Carolina Received Received
  532-P ADDITION OF PLERIXAFOR TO G-CSF IMPROVES THE GRAFT CONTENT IN SIDE POPULATION (SP) WITH IMMATURE PHENOTYPE IN PATIENTS THAT FAILED TO RESPOND WELL TO G-CSF ALONE. Bijou Fontanet Carolina Received Received
  533-P THE IRON CHELATOR DEFERASIROX AFFECTS REDOX SIGNALING IN HEALTHY HEMATOPOIETIC STEM CELLS Piccoli Claudia Carolina Received Received
  534-P INTERACTIONS BETWEEN MULTIPOTENT MESENCHYMAL STROMAL CELLS AND HEMATOPOIETIC PROGENITOR CELLS ALTER AFTER INTERLEUKIN 1 BETA ADMINISTRATION Drize Nina Ryun Received Received
  536-P MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITS OVEREXPANSION OF IMMATURE ERYTHROID CELLS IN THE SPLEEN DURING CHRONIC PSYCHOLOGICAL STRESS Budec Mirela Ryun Received Received
  538-P THE SPECTRUM OF ADULT´S PARVOVIRUS B19 INFECTION IN HOSPITAL ACCORDING TO THE CLINICAL BACKGROUND: REPORT OF A SINGLE CENTER EXPERIENCE AND PROPOSALS FOR THE CLINICAL PRACTICE. Wagner-Ballon Orianne Carolina Received Received
  539-P CONTINUOUS ERYTHROPOIETIC ACTIVITY OF EPOETIN BETA PEGOL IN A GENE-MODIFIED MOUSE MODEL FOR ERYTHROPOIETIN-DEFICIENCY ANAEMIA Suzuki Norio Ryun Received Received
  540-P CATION LEAK ANALYSIS OF ABCB6 MUTANTS IN FAMILIAL PSEUDOHYPERKALEMIA Andolfo Immacolata Carolina Received Received
  541-P GENETIC MARKERS AND FETAL HEMOGLOBIN (HBF) PRODUCTION: ASSOCIATION STUDY IN DELTABETA THALASSEMIA De La Fuente Received Received
  542-P MITOGEN-STIMULATED DIRECT ANTIGLOBULIN TEST IN PATIENTS WITH HEREDITARY SPHEROCYTOSIS zaninoni Anna Fuente Received Received
  544-P THE REDUCTION OF PEROXIREDOXINS ACTIVITY ARE CORELATED WITH THE INCREASE OF REACTIVE OXYGEN SPECIES (ROS) AND CELL HEMOLYSIS OBSERVED IN PATIENTS WITH HEMOLITIC ANEMIAS Anderson Cunha Received Received
  545-P HYPERTHERMIA INDUCES ERYPTOSIS IN HEREDITARY SPHEROCYTOSIS Crisp Renee Ryun Received Received
  546-P HAMP GENE MUTATION ASSOCIATED WITH JUVENILE HEMOCHROMATOSIS IN BRAZILIAN FAMILY Santos Paulo Ryun Received Received
  547-P HB CERVANTES, HB MARAÑÓN, HB LA MANCHA AND HB GOYA: DESCRIPTION OF FOUR NEW HEMOGLOBINOPHATIES De La Fuente Received Received
  549-P INFLUENCE OF HBG2 XMNI POLYMORPHISM ON HBF LEVELS IN PORTUGUESE BETA-THALASSEMIA CARRIERS Manco Licinio Ryun Received Received
  550-P MOLECULAR CHARACTERIZATION OF THE MUTATIONS CAUSING G6PD DEFICIENCY AMONG EGYPTIAN CHILDREN WITH GENOTYPE - PHENOTYPE CORRELATION ADLY Amira Fuente Received Received
  551-P EXTRAMEDULLARY HEMATOPOIESIS (EMH) IS ASSOCIATED WITH A THALASSAEMIA INTERMEDIA-LIKE PATTERN OF MYOCARDIAL AND LIVER IRON LOADING IN REGULARLY POLYTRANSFUSED THALASSAEMIA PATIENTS Meloni Antonella Ryun Received Received
  552-P MAGNETIC RESONANCE IMAGING T2 AND R2* TECHNIQUES REFLECT RENAL HEMOSIDEROSIS IN PATIENTS WITH THALASSEMIA AND SICKLE-CELL DISEASE; CORRELATIONS WITH SERUM FERRITIN AND MARKERS OF HEMOLYSIS Christoulas Dimitrios Fuente Received Received
  553-P HEPATIC FIBROSIS AND CIRRHOSIS IN PATIENTS WITH THALASSAEMIA MAJOR IS ASSOCIATED WITH PRESENT AND HISTORICAL IRON OVERLOAD, AGE, AND ACTIVE HEPATITIS C INFECTION Pasricha Sant-Rayn Ryun Received Received
  554-P FIBROSCAN FOR THE DETECTION OF LIVER FIBROSIS IN HAEMOGLOBINOPATHY PATIENTS REQUIRING CHRONIC TRANSFUSION THERAPY Gasiorowski Robin Fuente Received Received
  555-P EFFECT OF SPLENECTOMY ON CARDIAC IRON AND FUNCTION IN DIFFERENT TRANSFUSION-DEPENDENT PATIENTS Meloni Antonella Ryun Received Received
  557-P VENOUS THROMBOEMBOLISM IN SICKLE CELL DISEASE: PREVALENCE AND PATIENT CHARACTERISTICS. van Hamel Parsons Received Received
  560-P SOLUBLE FMS-LIKE TYROSINE KINASE-1 IN YOUNG PATIENTS WITH SICKLE CELL DISEASE: RELATION TO HEMOLYSIS-ASSOCIATED COMPLICATIONS Tantawy Azza Parsons Received Received
  561-P GROWTH DIFFERENTIATION FACTOR-15 IN CHILDREN AND ADOLESCENTS WITH SICKLE CELL DISEASE: RELATION TO HEMOLYSIS, IRON OVERLOAD AND VASCULAR COMPLICATIONS Tantawy Azza Parsons Received Received
  563-P OUTCOMES OF A COHORT OF CHILDREN WITH HEMOGLOBINOPATHY RECEIVING ORAL IRON CHELATORS FOR TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN TURKEY: 24-MONTH FOLLOW-UP Antmen Bulent Parsons Received Received
  564-P NON-TRANSFERRIN BOUND IRON REVISITED: NOW THAT ITS POTENTIAL TOXICITY IS ESTABLISHED, HOW CAN ITS MEASUREMENT HELP TO GUIDE CHELATION BERDOUKAS Vasilios Ryun Received Received
  565-P CHARACTERIZATION OF RARE ?LPHA-GLOBIN GENE MUTATIONS IN THAILAND Uaprasert Noppacharn Parsons Received Received
  568-P VARICELLA-ZOSTER VIRUS INFECTIONS IN IMMUNOCOMPROMISED PATIENTS; COMPARISON OF HEMATOLOGY – ONCOLOGY PATIENTS AND OTHER CHRONIC DISEASES Yoruk Asim Ryun Received Received
  569-P CHANGING OF PLATELET DERIVED MICROPARTICLES, SCUBE-1 AND IL-1? IN CHILDREN WITH DENGUE INFECTION Sosothikul Darintr Ryun Received Received
  571-P ROLE OF PROPHYLAXIS WITH LAMIVUDINE IN MAINTENANCE TREATMENT WITH RITUXIMAB IN NON HODGKIN LYMPHOMA CD20+ Cerchione Claudio Parsons Received Received
  572-P THE IMPACT OF HEPATITIS B VIRUS (HBV) INFECTION ON PROGNOSIS OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA AND THE OCCURRENCE OF HEPATITIS FLARES AFTER WITHDRAWAL OF PROPHYLACTIC ANTIVIRAL TREATMENT Law Man Fai Received Received
  573-P PREVALENCE, CHARACTERISTICS AND MANAGEMENT OF OCCULT HEPATITIS B VIRUS INFECTION (OBI) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS. MONOCENTRIC EXPERIENCE. Laurenti Luca Fai Received Received
  574-P SAFE RITUXIMAB ADMINISTRATION TO NHL PATIENTS WITH CONCOMITANT HBV ACTIVE INFECTION: THE RISK OF HBV REACTIVATION SHOULD NOT PREVENT US TO DELIVER OPTIMAL TREATMENT Zilioli Vittorio Brito Received Received
  575-P A RETROSPECTIVE ANALYSIS OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH MALIGNANT LYMPHOMAS WHO HAVE NOT RECEIVED HEMATOPOIETIC STEM CELL TRANSPLANTATION Sato Kazuya Fai Received Received
  576-P TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION DOESN´T INCREASE THE RISK OF SYMPTOMATIC CYTOMEGALOVIRUS REACTIVATION IN MYELOMA PATIENTS IN THE ERA OF NOVEL AGENTS: A SINGLE INSTITUTION STUDY MARCHESI Francesco Ryun Received Received
  577-P IMPACT OF NOSOCOMIAL VIRAL INFECTION IN CHILDREN UNDERGOING INTENSIVE CHEMOTHERAPY OR STEM CELL TRANSPLANTATION FOR HEMATOLOGIC OR MALIGNANT DISEASE Yagasaki Hiroshi Brito Received Received
  578-P CLINICAL CHARACTERISTICS AND OUTCOMES OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS Gijima Desire Fai Received Received
  579-P THE CLINICAL SPECTRUM AND OUTCOMES OF HUMAN HERPESVIRUS 6-RELATED INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Hegerova Livia Ryun Received Received
  580-P ANALYSIS OF PNEUMONIA IN ACUTE LEUKEMIA: A PROSPECTIVE STUDY BY THE "RETE EMATOLOGICA LOMBARDA" (REL) Mancini Valentina Fai Received Received
  581-P INFECTIONS IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME ON TREATMENT WITH AZACYTIDINE: EXPERIENCE OF A SINGLE CENTER. Lakhwani Sunil Ryun Received Received
  582-P ASSESSMENT OF INFECTION EVENTS IN AZACITIDINE (AZA) TREATMENT FOR MYELODYSPLASTIC SYNDROME (MDS) AND ACUTE MYELOID LEUKEMIA (AML). A SINGLE CENTRE EXPERIENCE. Romero Pilar Fai Received Received
  584-P ADMISSION OF PATIENTS WITH HEMATOLOGIC MALIGNANCES TO INTENSIVE CARE UNITS Badior Margarida Fai Received Received
  585-P PROSPECTIVE OBSERVATIONAL STUDY ON CHEMOTHERAPY- INDUCED NAUSEA AND VOMITING (CINV) FOR HEMATOLOGIC MALIGNANCY PATIENTS AND PRIMARY CARE MEDICAL STAFF´S PERCEPTION BY THE CINV STUDY GROUP OF JAPAN Yoshida Isao Brito Received Received
  587-P BUFFY COAT POOLED PLATELETS CRYOPRESERVED IN DIMETHYL-SULPHOXIDE WITH A NEW SYSTEM PRESERVE THEIR IN VITRO FUNCTION UP TO 9 MONTHS siragusa Sergio Fai Received Received
  588-P HEMOSTATIC FUNCTION AND BIOMARKERS OF ENDOTHELIAL DAMAGE BEFORE AND AFTER PLATELET TRANSFUSION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Larsen Anne Fai Received Received
  590-P ASSESSING RISK OF BLEEDING IN THROMBOCYTOPENIC PATIENTS REQUIRING PLATELET TRANSFUSION PRIOR TO INVASIVE PROCEDURES Al Zaabi Mohamed Received Received
  591-P RED CELL BLOOD GROUP GENOTYPING IN A COHORT OF BLOOD DONORS: FOCUS ON THE DUFFY ANTIGEN SYSTEM Colpo Anna Brito Received Received
  593-P RED BLOOD CELL ALLOIMMUNIZATION IN 18 – 50 YEAR OLD TRANSFUSED WOMEN A 3 YEAR STUDY MONCHARMONT Pierre Brito Received Received
  594-P RED BLOOD CELLS ALLOIMMUNIZATION IN POLYTRANSFUSED PATIENTS. Lucea Irene Mohamed Received Received
  595-P IDENTIFICATION OF ABCB6 GENETIC VARIANTS WITH LOW OR ABSENT PROTEIN EXPRESSION AS THE GENETIC BASIS OF HIGH FREQUENCY BLOOD GROUP ANTIGEN LANGEREIS Koszarska Magdalena Received Received
  596-P ANALYSIS OF ADVERSE REACTIONS IN VOLUNTARY WHOLE BLOOD DONORS: EXPERIENCE FROM A GREEK BLOOD CENTRE Girtovitis Fotios Mohamed Received Received
  599-P EVALUATION OF BILIARY INJURY IN NEWBORNS WITH ABO INCOMPATIBILITY El-Farrash Rania Received Received
  602-P FEASIBILITY OF ROMIPLOSTIM DISCONTINUATION IN ADULT TPO-MIMETIC RESPONSIVE PATIENT WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): AN OBSERVATIONAL RETROSPECTIVE REPORT IN REAL LIFE CLINICAL PRACTICE Carpenedo Monica Brito Received Received
  604-P A PROSPECTIVE, MULTICENTER, OPEN-LABEL STUDY OF RECOMBINANT HUMAN THROMBOPOIETIN ON PLATELET RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION ZHOU Hongsheng Mohamed Received Received
  605-P SHORT TERM RE-EXPOSURE TO ROMIPLOSTIM IN PREVIOUSLY TPO-MIMETIC RESPONSIVE ITP PATIENTS ALLOWS RECOVERY OF PLATELET COUNT AND LONG TERM SUSTAINED REMISSION: AN OBSERVATIONAL RETROSPECTIVE CASE-SERIES Carpenedo Monica Brito Received Received
  606-P THROMBOPOIETIN RECEPTOR AGONISTS IN PRIMARY IMMUNE THROMBOCYTOPENIA: EVALUATION OF EFFICACY (RESPONSE AND SUSTAINED RESPONSE OFF-TREATMENT) AND SAFETY IN A SINGLE CENTER POPULATION. Santoro Cristina Mohamed Received Received
  607-P PREDICTIVE FACTORS ASSOCIATED WITH LONG-TERM EFFECTS OF SPLENECTOMY FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA Mitrovic Mirjana Mohamed Received Received
  608-P THROMBOPOIETIN RECEPTOR AGONISTS AFFECTS THE LEVELS OF HEPATOCYTE GROWTH FACTOR AND TRANSFORMING GROWTH FACTORS IN IMMUNE THROMBOCYTOPENIA GHANIMA Waleed Brito Received Received
  609-P PREOPERATIVE USE OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP PATIENTS PRIOR TO SPLENECTOMY OR CARDIOVASCULAR SURGERY. De Stefano Valerio Received Received
  610-P A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF 57 A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF 57 CONSECUTIVE LAPAROSCOPIC SPLENECTOMIES IN PATIENTS WITH IMMUNE THROMBOCYTOPENIC PURPURA Novelli Silvana Ryun Received Received
  611-P THE TREATMENT WITH ELTROMBOPAG OF THE REFRACTORY ITP Gaman Mihnea-Alexandru Ryun Received Received
  612-P THROMBOPOIETIC AGENTS INCREASE PLATELET COUNTS MORE EFFECTIVELY IN ITP PATIENTS WITH HIGHER PLATELET PRODUCTION PRIOR TO TREATMENT Alexandra Kruse Received Received
  614-P ROMIPLOSTIM: EFFICACY AND SAFETY IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP). SINGLE CENTRE EXPERIENCE Zotova Irina Ryun Received Received
  615-P CORRELATION BETWEEN OXIDATIVE STRESS AND BIOMARKERS OF JOINT DAMAGE IN PATIENTS WITH SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGIMENS Djunic Irena Valerio Received Received
  616-P BONE MINERAL DENSITY IN MEN AND CHILDREN WITH HAEMOPHILIA A AND B: A SYSTEMATIC REVIEW AND META-ANALYSIS Anagnostis Panagiotis Received Received
  618-P APPLICATION OF THE US NATIONAL INSTITUTE OF HEALTH (NIH) 2008 GUIDELINES FOR VON WILLEBRAND DISEASE IN A NATIONAL PAEDIATRIC COMPREHENSIVE CARE CENTRE. Regan Irene Valerio Received Received
  620-P MONITORING OF SUBSTITUTION THERAPY WITH RECOMBINANT FACTOR XIII OF A PATIENT WITH SEVERE FACTOR XIII A SUBUNIT DEFICIENCY Muszbek László Valerio Received Received
  621-P OPTIMAL MANAGEMENT OF A RARE COAGULATION DISORDER: FACTOR V DEFICIENCY Elshinawy Mohamed Valerio Received Received
  622-P THE CLINICOLABORATORY CHARACTERISTICS AND TREATMENT OUTCOMES OF 10 KOREAN PATIENTS WITH FACTOR V DEFICIENCY Park Young Hoon Received Received
  623-P DETECTION OF ANTI-THROMBOPOIETIN AUTOANTIBODY AMONG IMMUNE THROMBOCYTOPENIC PATIENTS Miyazaki Koji Hoon Received Received
  624-P HOMOZYGOUS PROTEIN C DEFICIENCY: A DESCRIPTION OF TWO NEW CASES AND LONG-TERM SURVIVAL OF A THIRD CASE SUCCESSFULLY TREATED WITH ORAL ANTICOAGULANT THERAPY, A REPORT FROM SAUDI ARABIA Elborai Yasser Ryun Received Received
  625-P AN AUDIT TO DETERMINE THE SAFETY OF THE NOVEL ORAL ANTICOAGULANTS, DABIGATRAN AND RIVAROXABAN, FOR PATIENTS INITIATED ON ANTICOAGULANT THERAPY kurunadalingam Hariney Hoon Received Received
  626-P COMPREHENSIVE SYMPTOM PROFILE IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: PRACTICABILITY AND SENSITIVITY OF THE NEW SYMPTOM ASSESSMENT TOOL CSP LEUK-CML Nikitina Tatiana Ryun Received Received
  628-P THE VALUE OF DASATINIB THERAPY IN PATIENTS WITH IMATINIB-RESISTANT OR -INTOLERANT CHRONIC MYELOID LEUKEMIA FROM PHYSICIAN´S AND PATIENT´S PERSPECTIVE: "REAL WORLD" OUTCOMES Nikitina Tatiana Ryun Received Received
  629-P COVARIATION OF PSYCHOLOGICAL AND INFLAMMATORY VARIABLES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA RECEIVING IBRUTINIB Maddocks Kami Received Received
  631-P BONE MARROW ASPIRATION: A RANDOMIZED TRIAL ON THE QUALITY OF THE BONE MARROW SPECIMEN USING SLOW OR RAPID ASPIRATION TECHNIQUES AND ASSESSMENT OF THE PAIN INTENSITY Jensen Paw Ryun Received Received
  632-P IMPACT OF ANEMIA ON HEALTH-RELATED QUALITY-OF-LIFE AND CARDIAC REMODELING IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS). RESULTS OF GLOBQOL OBSERVATIONAL PROSPECTIVE STUDY. RAMOS Fernando Hoon Received Received
  634-P A FEASIBILITY STUDY OF VIRTUAL REALITY EXERCISE USING WII FIT AMONG PATIENTS WITH HEMATOLOGIC MALIGNANCIES RECEIVING CHEMOTHERAPY Tsuda Kenji Ryun Received Received
  636-P EDUCATIONAL INTERVENTION IN CANCER PATIENTS: THE IMPACT OF A CANCER SYMPOSIA ON PATIENT KNOWLEDGE Padrnos Leslie Brito Received Received
  638-P BURDEN OF ILLNESS OF PATIENS WITH CHRONIC LYMPHOCYTIC LEUKEMIA THAT ARE REFRACTORY TO FLUDARABINE AND ALEMTUZUMAB-CONTAINING REGIMENS IN SPAIN: AVERAGE COST ESTIMATION BY MONTECARLO SIMULATION Parrondo García Javier Received Received
  640-P PERSPECTIVE OF CHILDREN WITH CANCER ABOUT CANCER RELATED FATIGUE : A SINGLE CENTER EXPERIENCE Hesham Mervat Ryun Received Received
  747-P TARGETING THE DOPAMINE RECEPTOR SIGNALING REDUCES THE POLYCOMB PROTEIN BMI1 AND LIMITS THE SELF-RENEWAL OF BCR-ABL1 POSITIVE LEUKEMIA CELLS Tauchi Tetsuzo Javier Received Received
  748-P COMPLEX GENETIC HETEROGENEITY INFLUENCES PROGNOSIS IN ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA NEGATIVE FOR RECURRENT FUSION GENES Iacobucci Ilaria Javier Received Received
  754-P CD20 EXPRESSION IN ADULTS WITH PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) FROM UKALL14, ITS REGULATION BY DEXAMETHASONE AND RITUXIMAB INDUCED CYTOTOXICITY Beaton Brendan Javier Received Received
  755-P INHIBITION OF CLASS I PHOSPHATIDYLINOSITOL 3-KINASES (PI3KS) ISOFORMS IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL): WHICH IS THE BEST THERAPEUTIC STRATEGY? Lonetti Annalisa Javier Received Received
  757-P "GENOMIC INVERSE PCR FOR EXPLORATION OF LIGATED BREAKPOINTS" (GIPFEL) - A NEW METHOD TO DETECT THE MOST COMMON TRANSLOCATIONS IN CHILDHOOD LEUKEMIA Hoell Jessica Javier Received Received
  759-P SIGNIFICANCE OF ADDITIONAL STRUCTURAL ABERRATIONS IN BONE MARROW CELLS OF 115 CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND HIGH HYPERDIPLOIDY Lizcova Libuse Javier Received Received
  761-P A COMPREHENSIVE NEW DNA TEST FOR DETECTION OF FUSION GENES IN LEUKEMIA van den Berg-de Received Received
  766-P 6-MERCAPTOPURINE DOSAGE REDUCTION AND TPMT POLYMORPHISMS IN THE TREATMENT OF CHILDREN ACUTE LYMPHOBLASTIC LEUKEMIA Ferreira Baptista Ana Received Received
  767-P FREQUENCY AND CLINICAL SIGNIFICANCE OF OCCULT CENTRAL NERVOUS SYSTEM INVOLVEMENT AT DIAGNOSIS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS VILA-BOU Jordi Helena Received Received
  768-P TREATMENT OF RELAPSED ACUTE LEUKEMIA AFTER ALLO-HSCT BY SALVAGE CHEMOTHERAPY WITH LOW-DOSE CYTARABINE AND ACLARUBICIN COMBINED WITH G-CSF PRIMING: MORE EFFECTIVE AND LESS TOXIC? Wu Depei Ryun Received Received
  769-P QUANTITATIVE ULTRASOUND OF PROXIMAL PHALANXES IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA SURVIVORS De Matteo Antonia Received Received
  770-P RELATIONSHIP BETWEEN MTHFR POLYMORPHISM AND SIDE EFFECTS OF HIGH-DOSE METHOTREXATE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA ragab Seham Ana Received Received
  772-P MINIMAL RESIDUAL DISEASE IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA - A SWEDISH POPULATION-BASED STUDY Bergfelt Emma Ana Received Received
  773-P INVASIVE FUNGAL INFECTIONS IN PEDIATRIC PATIENTS WITH ACUTE LEUKEMIA: RESULTS FROM AN UNIVERSITY HOSPITAL, 2005 TO 2013 Sahbudak Bal Zümrüt Received Received
  774-P ASPARAGINASE-ASSOCIATED PANCREATITIS (AAP) DURING TREATMENT FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) Garrido Teresa Ana Received Received
  775-P MOLECULAR CYTOGENETIC ANALYSIS IN 108 CHILDHOOD ACUTE LEUKEMIA PATIENTS FROM SAUDI ARABIA: CORRELATION TO MOLECULAR AND OTHER BIOLOGIC FACTORS Elborai Yasser Antonia Received Received
  776-P LENALIDOMIDE FOR TREATMENT OF REFRACTORY/RELAPSED ADULT B-ALL PATIENTS: RESULTS OF A MULTICENTRIC PHASE 2 STUDY. Tavernier-Tardy Emmanuelle Received Received
  778-P TRANSFUSION IRON INTAKE IN TRANSPLANT ELIGIBLE PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA: RETROSPECTIVE ANALYSIS OF IRON LOAD AT THE END OF CHEMOTHERAPY PROGRAM AND BEFORE TRANSPLANTATION Belotti Angelo Javier Received Received
  780-P COPY NUMBER GAINS OF CHROMOSOME 1P36 LEAD TO PRDM16 OVEREXPRESSION IN AML PATIENTS Baldazzi Carmen Ana Received Received
  781-P CHARACTERIZATION OF THE RARE TRANSLOCATION T(3;10)(Q26;Q21) IN AN ACUTE MYELOID LEUKEMIA PATIENT Jancušková Tereza Helena Received Received
  782-P GSX2 DEREGULATION IN CD7+ ACUTE MYELOID LEUKEMIA BEARING 4Q12 TRANSLOCATIONS WITHOUT FUSION GENES Di Giacomo Danika Received Received
  783-P TELOMERE LENGTH IS SIGNIFICANTLY SHORTENED IN AML PATIENTS IN CYTOGENETIC REMISSION: POSSIBLE IMPLICATIONS ON THE ORIGIN OF AML Ventura Ferreira Monica Received Received
  784-P COMPLEX CHROMOSOMAL REARRANGEMENTS LEADING TO EVI1 OVEREXPRESSION ARE RECURRENT MECHANISMS IN CASES WITH VARIOUS 3Q ABNORMALITIES Baldazzi Carmen Monica Received Received
  785-P DEVELOPMENT OF MOLECULAR BEACON BASED PCR ASSAY FOR EASY DETECTION AND QUANTIFICATION OF CHIMERIC TRANSCRIPTS OF AML-ETO [T(8;21)] IN ACUTE MYELOID LEUKEMIA PATIENTS Arora Rashi Monica Received Received
  786-P ANALYSIS OF NPM1 SPLICE VARIANTS REVEALS DIFFERENTIAL EXPRESSION PATTERNS OF PROGNOSTIC VALUE IN ACUTE MYELOID LEUKEMIA Zajac Malgorzata Monica Received Received
  787-P HIGH LEVELS OF HOTAIRM1, A LONG INTERGENIC NON-CODING RNA RELATED TO HOX GENES, IS ASSOCIATED WITH POOR PROGNOSIS AND A DISTINCTIVE MICRORNA SIGNATURE IN INTERMEDIATE-RISK ACUTE MYELOID LEUKEMIA diaz beya Marina Received Received
  788-P CD123 (IL-3R?) IS CONSISTENTLY EXPRESSED ON ACUTE MYELOID LEUKEMIA (AML) CARRYING NUCLEOPHOSMIN (NPM1) GENE MUTATION Brunetti Lorenzo Monica Received Received
  789-P THE PROGNOSTIC VALUE OF LEUKEMIC STEM CELLS IN PEDIATRIC AML. De Caluwé Bram Received Received
  790-P BCL11B UP-REGULATION IN ACUTE MYELOID LEUKEMIA WITH CD2 T-ANTIGEN EXPRESSION AND FLT3 MUTATION Brandimarte Lucia Monica Received Received
  791-P PSEUDO-EXHAUSTION OF T CELLS IN RELAPSED AML Lichtenegger Felix Monica Received Received
  794-P NFATC1 MEDIATES SORAFENIB RESISTANCE IN FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA Burchert Andreas Monica Received Received
  795-P EXPRESSION OF FLT3-ITD DYSREGULATES THE DBC1-SIRT1-P53 SIGNALING AND PROMOTES THERAPY RESISTANCE Sasca Daniel Monica Received Received
  798-P PRE-CLINICAL ACTIVITY OF THE PI3K INHIBITOR BKM120 ON ACUTE MYELOID LEUKEMIA Allegretti Matteo Monica Received Received
  799-P THE CXCR4 ANTAGONIST BL-8040 SYNERGIZES WITH THE FLT3 INHIBITOR AC220 TO INDUCE APOPTOSIS AND REDUCE MINIMAL RESIDUAL DISEASE OF AML CELLS IN VIVO Abraham Michal Monica Received Received
  804-P A NOVEL CLEC12AXCD3 BISPECIFIC ANTIBODY EFFICIENTLY INDUCES T-CELL MEDIATED LYSIS OF CLEC12A+ AML BLASTS Hangalapura Basav Bram Received Received
  805-P CATHECHOLAMINES DIFFERENTLY REGULATE HUMAN AML AND NORMAL HEMATOPOIETIC PROGENITOR CELL MOTILITY VIA MIR126 AND RGS16 Avigdor Abraham Helena Received Received
  806-P CELL-TO-CELL COMMUNICATION IN ACUTE MYELOID LEUKEMIA BY TUNNELING NANOTUBES Omsland Maria Monica Received Received
  808-P GLYCOLYSIS INHIBITION ON ACUTE MYELOID LEUKEMIA Mirabilii Simone Monica Received Received
  810-P THE ROS/SUMO AXIS IS INVOLVED IN ACUTE MYELOID LEUKEMIA (AML) CELLS RESPONSE TO CHEMOTHERAPEUTIC DRUGS AND CONSTITUTES A POTENTIAL TARGET TO OVERCOME CHEMORESISTANCE IN AML bossis Guillaume Monica Received Received
  811-P ARSENIC TRIOXIDE AND FUCOIDAN SYNERGIZE TO INDUCE APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA Atashrazm Farzaneh Monica Received Received
  812-P THE PROGNOSTIC RELEVANCE OF THE 2008 WHO CLASSIFICATION OF MYELOID NEOPLASMS IN CHILDHOOD ACUTE MYELOID LEUKEMIA Kinoshita Akitoshi Monica Received Received
  813-P REVISITING THE CLONAL DYNAMICS OF TRISOMY 21 AND MONOSOMY 7 MOSAICISM IN CONGENITAL NEUTROPENIA AML Ünalan Murat Zümrüt Received Received
  814-P A SIMPLE AND EFFECTIVE STRATEGY TO DECREASE EARLY DEATHS IN ACUTE PROMYELOCYTIC LEUKEMIA USING A STREAMLINED SET OF GUIDELINES PAIRED WITH EXPERT SUPPORT. kota Vamsi Monica Received Received
  815-P INCIDENCE AND TYPE OF IDH1 AND IDH2 MUTATIONS IN AML-NK PATIENTS AND THEIR PROGNOSTIC IMPACT ON TREATMENT OUTCOME Kim Yeo-Kyeoung Monica Received Received
  816-P SCREENING OF TP53 (TUMOR PROTEIN 53) MUTATIONS IN ADULT ACUTE MYELOID LEUKEMIA (AML) PATIENTS REVEALS A STRONG ASSOCIATION WITH COMPLEX KARYOTYPE AND POOR OUTCOME Ferrari Anna Bram Received Received
  822-P VALIDATION OF SIE/SIES/GITMO "FITNESS CRITERIA" FOR ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA: APPLICABILITY AND OUTCOME ANALYSIS ACCORDING TO FITNESS AND TO TREATMENT RECEIVED. borlenghi Erika Monica Received Received
  823-P C-KIT MUTATION IN CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA: PREVALENCE AND PROGNOSTIC ROLE IN TAIWAN. EXPERIENCE OF ONE SINGLE INSTITUTION Lee Linkun Bram Received Received
  824-P ADVERSE PROGNOSTIC IMPACT OF IDH MUTATIONS ON OUTCOME IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE Virijevic Marijana Monica Received Received
  826-P COMBINED USE OF MULTI-COLOR FCM AND PCR ANALYSIS CAN DETECT LESS THAN 0.01% PATHOLOGICAL CELLS IN THE VAST MAJORITY OF DE NOVO AML CASES Kazuma Yasuhiro Monica Received Received
  827-P INDOLEAMINE 2,3-DIOXYGENASE-1 (IDO-1) IS ASSOCIATED WITH HIGH INCIDENCE OF CHEMOREFRACTORY DISEASE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS Parisi Sarah Monica Received Received
  829-P INTEREST OF CYTOGENETIC AND FISH EVALUATION FOR PROGNOSIS EVALUATION IN 198 PATIENTS WITH ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION IN A SINGLE INSTITUTION Hirsch Pierre Monica Received Received
  830-P ACUTE MYELOID LEUKEMIA IN PATIENTS OLDER THAN 75: PROGNOSTIC IMPACT OF FLT3-ITD AND NPM1 MUTATIONS Hirsch Pierre Monica Received Received
  831-P MOLECULAR RELEVANCE OF THE NERVE GROWTH FACTOR RECEPTOR GENE (NTRK1) EXPRESSION IN AML-RELATED MYELOID SARCOMA lazzaroni Francesca Bram Received Received
  832-P ELN FAVORABLE ACUTE MYELOID LEUKEMIA SHARE THE SAME GOOD PROGNOSIS ACROSS CYTOGENETIC/MOLECULAR SUBGROUPS: PRELIMINARY RETROSPECTIVE REAL-LIFE ANALYSIS OF THE RETE EMATOLOGICA LOMBARDA (REL) Zappasodi Patrizia Monica Received Received
  833-P A POST-REMISSION MAINTENANCE TREATMENT WITH LOW-DOSE CHEMOTHERAPY + RETINOIDS AND DIHYDROXYLATED VITAMIN D3 MAY IMPROVE THE SURVIVAL OF POOR-PROGNOSIS AML/MDS PATIENTS Ferrero Dario Monica Received Received
  834-P MDRO INFECTION THE ´´MAJOR HURDLE TO ACUTE MYELOID LEUKEMIA INDUCTION THERAPY" EXPERIENCE OF A TERTIARY CARE COMPREHENSIVE CANCER CENTER FROM INDIA. CHAKRAPANI Anupam Bram Received Received
  835-P ACQUIRED IDH1 AND IDH2 MUTATIONS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKAEMIA: THEIR PREVALENCE AND ASSOCIATION WITH OTHER GENE MUTATIONS – A SINGLE CENTRE EXPERIENCE How Gee Fung Received Received
  841-P NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS CAN BENEFIT FROM A SIGNIFICANT BETTER SURVIVAL WHEN INCLUDED IN CLINICAL TRIALS MICHALLET Mauricette Fung Received Received
  843-P COMPARATIVE ANALYSIS OF FOUR COURSES OF STANDARD-DOSE CONSOLIDATION WITHOUT MAINTENANCE VERSUS THREE COURSES OF LOW-INTENSITY CONSOLIDATION WITH MAINTENANCE IN ADULTS WITH ACUTE MIELOID LEUKEMIA SEMOCHKIN Sergey Fung Received Received
  844-P MN1 OVEREXPRESSION IS A POWERFUL PREDICTOR OF FAILURE OF INDUCTION CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIAS SUCH AS CONVENTIONAL CYTOGENETICS AND AGE. Rodríguez Carlos Fung Received Received
  846-P TARGETED ARRAYCGH USED FOR DETERMINING MINIMALLY DELETED REGION ON CHROMOSOME 6Q IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Jarosova Marie Bram Received Received
  848-P NOD/SCID GAMMA XENOGRAFT MODEL OF B-CELL MALIGNANCIES USING TP53- AND/OR ATM-DEFICIENT CELL LINES Verner Jan Fung Received Received
  849-P COPY NUMBER ALTERATIONS AND NOTCH1 MUTATIONS PREDICT THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND NORMAL FISH Delgado Julio Bram Received Received
  851-P TAP63 IS EPIGENETICALLY REGULATED AND HIGHLY OVEREXPRESSED IN AGGRESSIVE CLL STEREOTYPED SUBSET #8 Stamatopoulos Kostas Fung Received Received
  853-P CYTOGENETIC EVOLUTION PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA Iskas Michail Bram Received Received
  854-P CHARACTERIZATION AND SIGNIFICANCE OF RARE BALANCED IMMUNOGLOBULIN TRANSLOCATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA Van Obbergh Florence Received Received
  855-P IMPACT OF TWO CYTOGENETIC LESIONS ON THE OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Visentin Andrea Florence Received Received
  856-P SF3B1 MUTATIONS IN CLL ARE ASSOCIATED WITH A DEFECTIVE DNA DAMAGE RESPONSE Eldering Eric Fung Received Received
  857-P SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS Sellner Leopold Fung Received Received
  858-P TRISOMY 12 IS ASSOCIATED WITH A DISTINCT PATTERN OF LYMPHOCYTOSIS DURING TREATMENT OF CLL WITH IBRUTINIB, WHICH DOES NOT AFFECT RESPONSE DEPTH OR DURATION Thompson Philip Fung Received Received
  859-P INTEGRATION OF NOVEL GENE MUTATIONS INTO KARYOTYPE-BASED SUBGROUPS AS A PROGNOSTIC RISK STRATIFICATION TOOL IN CHRONIC LYMPHOCYTIC LEUKEMIA Del Giudice Ilaria Received Received
  862-P ITALIAN VALIDATION OF THE MDACC PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: ANALYSIS OF 1502 CASES. Gentile Massimo Helena Received Received
  864-P SKIN CANCERS ARE COMMON AND CAUSE CONSIDERABLE MORBIDITY IN PATIENTS TREATED WITH FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB FOR CHRONIC LYMPHOCYTIC LEUKAEMIA Tam Constantine Florence Received Received
  865-P A POPULATION BASED EXPERIENCE ON THE USE OF RCD OR RCVP IN AUTOIMMUNE HEMOLYTIC ANEMIA IN CLL Kumar Rajat Florence Received Received
  869-P OPEN LABEL MULTICENTER STUDY OF ELTROMBOPAG FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA SECONDARY TO LYMPHOPROLIFERATIVE DISORDERS Visco Carlo Florence Received Received
  870-P IS ZAP-70 STILL A KEY PROGNOSTIC FACTOR IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS OF THE ANALYSIS FROM A PROSPECTIVE MULTICENTER OBSERVATIONAL STUDY Gentile Massimo Ilaria Received Received
  871-P EVALUATION OF IMMUNE RESPONSE TO 13-VALENT PNEUMOCOCCAL CONJUGATED VACCINE (PCV13) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA Rolinski Jacek Florence Received Received
  872-P INITIAL CHARACTERISTICS, TREATMENT AND PROGNOSIS ACCORDING TO AGE IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A SINGLE-CENTER ANALYSIS BASED ON 949 PATIENTS. Baumann Tycho Florence Received Received
  873-P IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA A HIGH NUMBER OF CELLS WITH TRISOMY 12 IS ASSOCIATED WITH A POOR OUTCOME. ANALYSIS OF DATABASE OF SPANISH GROUPS OF CYTOGENETICS (GCECGH) AND CLL (GELLC) José-Ángel Hernández Florence Received Received
  874-P COMPARATIVE EFFECT OF BENDAMUSTINE PLUS RITUXIMAB (R) VS FLUDARABINE PLUS CYCLOPHOSPHAMIDE PLUS R ON THE LEVELS OF PERIPHERAL BLOOD LEUCOCYTE POPULATIONS IN ADVANCED-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA Barrena Susana Received Received
  877-P ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA Doubek Michael Romana Received Received
  878-P A PATHOLOGICAL ABDOMINAL ULTRASONOGRAPHY AT DIAGNOSIS OF CLL SIGNIFICANTLY REDUCES THE TIME TO PROGRESSION IN PATIENTS WITH RAI 0 OR 1 DISEASE Rossini Fausto Zümrüt Received Received
  879-P IN VITRO COMPARATIVE STUDY ON DIRECT KILLING OF CLL CELLS BY SMALL TARGETED THERAPEUTIC MOLECULES Eketorp Sylvan Received Received
  881-P DO CHRONIC MYELOID LEUKEMIA PATIENTS WITH LATE "WARNING" RESPONSES BENEFIT FROM SWITCHING THERAPY TO A SECOND GENERATION TYROSINE KINASE INHIBITOR? García-Gutiérrez Valentin Ilaria Received Received
  885-P DASATINIB PHARMACOKINETICS AND ITS CORRELATION WITH CLINICAL RESPONSE IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF THE DARIA-01 STUDY Miyao Kotaro Ilaria Received Received
  888-P LONG-TERM RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL OF HIGH-DOSE IMATINIB WITH OR WITHOUT INTERFERON-? IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE Koji Sasaki Received Received
  897-P OUTCOMES OF THIRD-LINE BCR-ABL1 TYROSINE KINASE INHIBITORS IN THE TREATMENT FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS WHO HAVE RECEIVED TWO PRIOR TKIS Lee Sung-Eun Sandra Received Received
  898-P PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA Lee Sung-Eun Sandra Received Received
  899-P OUTCOMES OF PREGNANCY AND THERAPEUTIC APPROACHES IN CHRONIC MYELOID LEUKEMIA DURING PREGNANCY Chelysheva Ekaterina Monica Received Received
  901-P CHROMOSOMAL ABNORMALITIES IN PHILADELPHIA CHROMOSOME (PH)-NEGATIVE METAPHASES IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE TREATED FRONTLINE WITH NILOTINIB OR DASATINIB Shah Shilpan Ilaria Received Received
  902-P CLINICAL EXPERIENCE OF BOSUTINIB UNDER COMPASIONATE USE PROGRAM IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH RESISTANCE OR INTOLERANCE TO IMATINIB, DASATINIB AND NILOTINIB García-Gutiérrez Valentin Ilaria Received Received
  904-P DESIGN OF RAPID FLUORESCENT MOLECULAR BEACON BASED PCR ASSAY FOR DETECTION AND QUANTIFICATION OF BCR –ABL TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA PATIENTS Jetly Sunita Ilaria Received Received
  905-P HYPOPHOSPHATEMIA AS A PREDICTOR OF RESPONSE IN CHRONIC MYELOID LEUKEMIA (CML) TREATED WITH IMATINIB Garrido Teresa Ilaria Received Received
  906-P RISK AND IMPACT OF TUBERCULOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY IN TAIWAN Liu Chia-Jen Ilaria Received Received
  907-P MULTICENTER CLINICAL STUDY TO EVALUATE A UTILITY OF FRET-BASED DRUG SENRITIVITY TEST THAT PREDICTS EARLY MOLECULAR RESPONSE IN NEWLY DIAGNOSED CML PATIENTS TREATED WITH NILOTINIB Kondo Takeshi Monica Received Received
  908-P FIRST PRELIMINARY REPORT OF ARAB LEUKEMIA NET (ALN) REGISTRY FOR CHRONIC MYELOID LEUKAEMIA (CML) IN THE MIDDLE EAST &NORTH AFRICA REGION.PART I EPIDEMIOLOGY OF CML IN EGYPT. AZZAZI Mohamed Ilaria Received Received
  913-P THE EFFECT OF DELAYED TKI TREATMENT ON CYTOGENETIC AND MOLECULAR RESPONSES: 8 YEAR FOLLOW-UP STUDY IN BOSNIA KURTOVIC Azra Sandra Received Received
  914-P THE TYROSINE KINASE INHIBITOR AXITINIB TARGETS T315I-MUTANT BCR-ABL DRIVEN LEUKEMIAS IN VITRO AND IN VIVO Pemovska Tea Ilaria Received Received
  916-P THE INFLUENCE OF DISEASE AND COMORBIDITY RISK ASSESSMENTS ON THE SURVIVAL OF MDS PATIENTS TREATED WITH 5-AZACITIDINE molteni Alfredo Sandra Received Received
  917-P IRON-CHELATING THERAPY WITH DEFERASIROX IN HIGHER RISK MYELODYSPLASTIC SYNDROMES: A RETROSPECTIVE, MULTICENTER, ITALIAN STUDY Musto Pellegrino Ilaria Received Received
  918-P MYELODYSPLASTIC SYNDROMES: AN INTEGRATED MOLECULAR/CYTOGENETIC WORKUP FOR A CORRECT PATIENTS´ RISK STRATIFICATION. GALIMBERTI Sara Ilaria Received Received
  920-P HIGHER BONE MARROW LGALS3 EXPRESSION PREDICTS FAVORABLE PROGNOSIS IN ADULT PATIENTS WITH MYELODYSPLASTIC SYNDROME Hou Hsin-An Ilaria Received Received
  921-P VALUE OF THE MULTIPARAMETRIC FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA UNDER HYPOMETHYLATING AGENT THERAPY. iastrebner Marcelo Sandra Received Received
  922-P CLINICAL VALUE OF MONOSOMAL KARYOTYPE AND COMPLEX KARYOTYPE AS PROGNOSTIC PARAMETER IN PATIENTS WITH IPSS INTERMEDIATE-2 AND HIGH RISK MYELODYSPLASTIC SYNDROMES TREATED WITH AZACITIDINE song Moo Kon Received Received
  924-P A PHASE II STUDY EXPLORING THE FEASIBILITY OF AZACITIDINE AND LENALIDOMIDE USE (COMBINATION VS SEQUENTIAL TREATMENT) FOR HIGHER-RISK MYELODYSPLASTIC SYNDROMES (IPSS RISK: HIGH OR INT-2) Finelli Carlo Kon Received Received
  925-P IMPACT OF GRAFT-VERSUS-HOST DISEASE ON OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES Aoki Jun Kon Received Received
  926-P IMPACT OF TP53 MUTATION ON OUTCOME OF MDS PATIENTS UNDERGOING ALLOGENEIC TRASPLANT Díez Campelo María Received Received
  927-P ISOCHROMOSOME 17Q10 IN MYELOID NEOPLASMS IS FREQUENTLY ASSOCIATED WITH MULTIPLE MUTATIONS AND TRANSFORMATION TO ACUTE MEGAKARYOBLASTIC LEUKEMIA ZHOU Hongsheng María Received Received
  929-P IMPACT OF HIGH-DOSE RADIATION EXPOSURE ON NAGASAKI ATOMIC BOMB SURVIVORS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH AZACITIDINE Jo Tatsuro María Received Received
  930-P TREG CELLS NUMBER FROM HIGH-RISK MYELODISPLASTIC SYNDROME PATIENTS IS INCREASE, BUT ITS SUPRESSION HABILITY IS IMPARED PERAZZIO Aline María Received Received
  931-P METHYLATION PATTERNS IN PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SINDROMES AND SECONDARY ACUTE MYELOID LEUKEMIA TREATED WITH HIPOMETHYLANT AGENTS (HIGH-RISK MDS 2009 PROTOCOL OF CETLAM GROUP). Cabezón Marta Monica Received Received
  932-P HIF-1? INHIBITION BLOCKS THE CROSS TALK BETWEEN MULTIPLE MYELOMA PLASMA CELLS AND TUMOR MICROENVIRONMENT Borsi Enrica Kon Received Received
  936-P PROTEASOME INHIBITORS MODULATE OSTEOCYTE DEATH AND AUTOPHAGY IN MULTIPLE MYELOMA. Giuliani Nicola María Received Received
  937-P THE METABOLIC STRESS INDUCED BY CYCLIN D1 IMPACTS CELL ADHESION, MIGRATION AND CELL ADHESION-MEDIATED DRUG RESISTANCE (CAM-DR) IN MYELOMA CELLS. Bustany Sophie Monica Received Received
  938-P CYCLIN D1 CONSTITUTIVE EXPRESSION SENSITIZES MULTIPLE MYELOMA CELLS TO BORTEZOMIB BY INHIBITING HEAT SHOCK PROTEINS. Bustany Sophie Monica Received Received
  939-P SERUM LEVELS OF DICKKOPF-1 PREDICT PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTAT BUT ITS PROGNOSTIC VALUE IS OVERCOME BY THE USE OF NOVEL DRUGS Minarik Jiri Kon Received Received
  940-P IMPACT OF EXONIZED ALUS ON SOLUBLE RANKL MRNA TRANSLATIONAL DYNAMICS. Papamichos Spyros Kon Received Received
  941-P FIBROBLAST ACTIVATION PROTEIN PROTECTS BORTEZOMIB INDUCED APOPTOSIS IN MULTIPLE MYELOMA CELLS THROUGH ?-CATENIN SIGNALING PATHWAY Cai Zhen Kon Received Received
  942-P PRECLINICAL ANTIMYELOMA ACTIVITY OF THE ALKYLATING-HDACI FUSION MOLECULE EDO-S101 THROUGH DNA-DAMAGING AND HDACI EFFECTS López-Iglesias Ana Alicia Received Received
  943-P SAR650984, A HUMANIZED ANTI-CD38 ANTIBODY, POTENTLY TARGETS CANCER CELLS THROUGH MULTIPLE MECHANISMS Cai Ti Monica Received Received
  944-P NETWORK OF MICRO RNA AND EPIGENETICS ARE ASSOCIATED WITH THE PROGRESSION OF MGUS AND MULTIPLE MYELOMA. Handa Hiroshi Alicia Received Received
  945-P CHARACTERIZATION OF SERUM AND GLUCOCORTICOID-INDUCIBLE KINASE 3 (SGK-3) AS A POTENTIAL ONCOGENIC ALTERNATIVE TO SIGNALLING VIA AKT IN MULTIPLE MYELOMA Seggewiss-Bernhardt Ruth Alicia Received Received
  946-P ORAL STATIN USE ASSOCIATED WITH REDUCED RISK OF MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND MULTIPLE MYELOMA: A POPULATION BASED NESTED CASE-CONTROL STUDY McShane Charlene Alicia Received Received
  948-P IMMUNE IMPAIRMENTS IN MULTIPLE MYELOMA BONE-MARROW MESENCHYMAL STROMAL CELLS André Thibaud Kon Received Received
  950-P PREVALENCE AND PROGNOSIS SIGNIFICANCE OF THE MYD88 (L265P) MUTATION IN IGM MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE AND SMOLDERING WALDENSTRÖM MACROGLOBULINEMIA Fernández de Received Received
  951-P INHIBITION OF NAMPT AUGMENTS IBRUTINIB INDUCED KILLING IN MYD88 L265P EXPRESSING WALDENSTROM`S MACROGLOBULINEMIA CELLS. Cagnetta Antonia de Received Received
  954-P COMPARISON OF THE N-LATEX AND FREELITE ASSAYS FOR SERUM FREE LIGHT CHAIN: CLINICAL PERFORMANCE IN AL AMYLOIDOSIS Palladini Giovanni de Received Received
  955-P CYSTATIN C BASED ESTIMATION OF GLOMERULAR FILTRATION RATE IN AL AMYLOIDOSIS Milani Paolo de Received Received
  956-P A PROFILE OF 140 LONG-TERM SURVIVORS WITH SYSTEMIC AL AMYLOIDOSIS Sachchithanantham Sajitha de Received Received
  961-P BENDAMUSTINE AND PREDNISONE IN COMBINATION WITH BORTEZOMIB (BPV) IN THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA. Poenisch Wolfram de Received Received
  962-P WHOLE-BODY LOW-DOSE CT (WBLDCT) IS USEFUL FOR DETECTION, STAGING, RESPONSE EVALUATION AND FOLLOW-UP IN MYELOMA PATIENTS Rossini Fausto de Received Received
  963-P PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE (VPD) AS INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA CANDIDATES TO AUTOLOGOUS TRANSPLANT mangiacavalli Silvia Kon Received Received
  969-P IMPACT OF CONSOLIDATION WITH BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTD) UPFRONT IN MULTIPLE MYELOMA (MM) WITH PARTIAL RESPONSE (PR) AT COMPLETION OF INDUCTION WITH VTD Leleu Xavier Kon Received Received
  975-P LONG TERM CRYOPRESERVED AUTOLOGOUS BLOOD STEM CELLS FOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED MULTIPLE MYELOMA PATIENTS Areethamsirikul Nuchanan Kon Received Received
  976-P MULTIPLE MYELOMA OF ELDERLY: COMORBIDITY INDEXES, SCALES, AND PERSONALIZED TREATMENT Djurasinovic Vladislava Monica Received Received
  977-P SMOULDERING MULTIPLE MYELOMA RISK FACTORS FOR PROGRESSION. AN ANALYSIS OF 289 CASES IN THE DANISH MULTIPLE MYELOMA REGISTRY Sørrig Rasmus Monica Received Received
  983-P A COMBINATION THERAPY WITH BORTEZOMIB (BOR) AND THALIDOMIDE IN NEWLY DIAGNOSED MYELOMA PATIENTS IS ASSOCIATED WITH A LOW INCIDENCE OF SECOND PRIMARY MALIGNANCIES (SPMS) Brioli Annamaria de Received Received
  984-P DIFFERENT OUTCOMES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION ACCORDING TO INVOLVED SITES IN MYELOMA PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMA: BONE VERSUS SOFT TISSUE PLASMACYTOMA Shin Ho-Jin Kon Received Received
  985-P EARLY MORTALITY TREND IN MULTIPLE MYELOMA: A THIRTY-YEAR POPULATION-BASED STUDY Ríos-Tamayo Rafael de Received Received
  988-P AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM) Nordström Eva Kon Received Received
  990-P ROLE OF IMMUNOHISTOCHEMISTRY IN THE DIAGNOSIS OF SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN AMYLOIDOSIS: RESULTS IN A SERIES FROM A SINGLE INSTITUTION Fernández de Received Received
  992-P IMPACT OF INITIAL FGD-PET CT AND SERUM FREE LIGHT CHAIN ON TRANSFORMATION OF CONVENTIONALLY DEFINED SOLITARY PLASMACYTOMA TO MULTIPLE MYELOMA FOUQUET Guillemette de Received Received
  993-P NEGATIVE FLOW CYTOMETRY IS ASSOCIATED WITH A BETTER PROGRESSION-FREE SURVIVAL IN TREATED MULTIPLE MYELOMA PATIENTS: THE SINGLE-CENTER EXPERIENCE OF CHU DE CAEN IN A DAILY PRACTICE Cabrera Quentin de Received Received
  994-P HIGH INCIDENCE OF INTACT IMMUNOGLOBULIN OR FRAGMENTS THEREOF IN URINE OF PATIENTS WITH MULTIPLE MYELOMA Kraj Maria de Received Received
  995-P VALIDATION OF THE SPECIFIC HEMATOPOIETIC-CELL-TRANSPLANTATION COMORBIDITY INDEX IN PATIENTS WITH MULTIPLE MYELOMA Jelicic Jelena de Received Received
  996-P RELATIONSHIP BETWEEN CHROMOSOMAL ABERRATIONS AND CLINICAL OR LABORATORY VARIABLES IN MULTIPLE MYELOMA Wawrzyniak Ewa de Received Received
  1000-P NUTRITIONAL COUNSELING IN SYSTEMIC IMMUNOGLOBULIN LIGHT-CHAIN (AL) AMYLOIDOSIS: A PROSPECTIVE RANDOMIZED, CONTROLLED TRIAL Palladini Giovanni Received Received
  1002-P BONE MARROW ASPIRATION SIGNIFICANTLY UNDERESTIMATES THE BURDEN OF DISEASE IN MULTIPLE MYELOMA AT DIAGNOSIS AND FOLLOW UP COMPARED WITH THE BONE MARROW TREPHINE Thomas Alison Received Received
  1004-P IMPACT OF NF?B1-94INS/DEL ATTG POLYMORPHISM ON DISEASE CHARACTERISTICS AND TREATMENT OUTCOME ON BORTEZOMIB BASED THERAPY IN PATIENTS WITH MULTIPLE MYELOMA Varga Gergely Received Received
  1005-P THIRD AUTOLOGOUS SALVAGE STEM CELL TRANSPLANT IN SUBJECTS WITH ADVANCED MULTIPLE MYELOMA Strifler Susanne Received Received
  1006-P TREATMENT WITH THE BILE-ACID SEQUESTRANT COLESEVELAM IMPROVES LENALIDOMIDE ASSOCIATED DIARRHOEA IN MYELOMA PATIENTS. PAWLYN Charlotte Received Received
  1007-P PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB Mian Michael Received Received
  1009-P EVALUATION OF VAD PROTOCOL IN MULTIPLE MYELOMA OVER A PERIOD OF 10 YEARS hanan Moussaoui Received Received
  1010-P A SIMPLE METHOD TO DETECT COPY NUMBER-NEUTRAL 6P-LOH IN PATIENTS WITH ACQUIRED APLASTIC ANEMIA USING DUPLEX QUANTITATIVE PCR Zaimoku Yoshitaka Received Received
  1011-P EPIGENETIC ALTERATIONS IN FANCONI ANAEMIA: ROLE IN DISEASE PROGRESSION AND THERAPEUTIC POTENTIAL Belo Hélio Received Received
  1012-P CHRONIC IDIOPATHIC NEUTROPENIA DOES NOT DISPLAY FREQUENT STAT3 MUTATIONS: IMPLICATIONS FOR DIFFERENTIAL DIAGNOSIS FROM OTHER CLINICAL SYNDROMES WITH T-CELL-MEDIATED SUPPRESSION OF HEMATOPOIESIS Stalika Evangelia Received Received
  1014-P PARAMETERS OF CELL IMMUNITY IN PATIENTS WITH APLASTIC ANEMIA AND THEIR RELATION TO PNH-CLONE Rozanova Olga Received Received
  1015-P ABNORMAL METABOLITES RELATED TO BONE MARROW FAILURE IN APLASTIC ANEMIA PATIENTS xing Cui Received Received
  1016-P PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CLINICAL EXPRESSION AND RESPONSE TO TREATMENT ARE MODIFIED BY A UNIQUE INTERACTION WITH CO-EXISTING GLUCOSE 6-PHOSPHATE DEHYDROGENASE DEFICIENCY Notaro Rosario Received Received
  1020-P INCREASED BONE MARROW (BM) PLASMA LEVELS OF SOLUBLE CD30 CORRELATE WITH BM PLASMA LEVELS OF INTERFERON (IFN)-GAMMA, CD4/CD8 T-CELL RATIO AND DISEASE SEVERITY IN APLASTIC ANEMIA zhang Jizhou Received Received
  1021-P EVALUATION OF GENETIC TESTING FOR FANCONI ANAEMIA: FROM SANGER TO NEXT GENERATION SEQUENCE ANALYSIS Goodeve Anne Received Received
  1022-P DIAMOND-BLACKFAN ANEMIA IN RUSSIAN FEDERATION Smetanina Nataliya Received Received
  1023-P TELOMERASE ENZYME ACTIVITY IN EGYPTIAN CHILDREN WITH E ANDBONE MARROW FAILUR RESPONSE TO IMMUNESUPRESSIVE THERAPY Elbeshlawy Amal Received Received
  1028-P PKC412 (MIDOSTAURIN) IS SAFE AND HIGHLY EFFECTIVE IN SYSTEMIC MASTOCYTOSIS PATIENTS: FOLLOW UP OF A SINGLE-CENTER ITALIAN COMPASSIONATE USE Papayannidis Cristina Received Received
  1029-P DIAGNOSTIC ACCURACY OF SERUM EPO LEVEL AND JAK2V617F ALLELE BURDEN IN POLYCYTHEMIA VERA Ancochea Agueda Received Received
  1030-P CALR MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA: INCIDENCE, CLINICAL UTILITY AND MOLECULAR DIAGNOSTIC BY HIGH RESOLUTION MELTING GOMEZ CASARES Maria Received Received
  1032-P YOUNG AGE IS NOT PROTECTIVE AGAINST THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA Randi Maria Luigia Received Received
  1035-P A PROGNOSTIC MODEL TO PREDICT THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA Lekovic Danijela Luigia Received Received
  1036-P CLINICAL FEATURES OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA DIAGNOSED BETWEEN THE AGES OF 41-59YEARS IN COMPARISON TO PATIENTS DIAGNOSED AT OR BELOW THE AGE OF 40 Kam Grace Received Received
  1037-P CARDIOVASCULAR EVENTS: RISK FACTORS AND CORRELATIONS WITH THE JAK2V617F ALLELE BURDEN IN PATIENTS WITH PH´-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS. A MONOCENTRIC STUDY. FONTANELLI Giulia Maria Received Received
  1038-P BACK TO LIFE -LIVING, TREATING, MANAGING MYELOFIBROSIS: THE BURDEN OF ILLNESS FOR PATIENTS AND THEIR FAMILIES Marini Maria Giulia Received Received
  1039-P GENDER DIFFERENCES AND MPN SYMPTOM BURDEN: AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG) Geyer Holly Giulia Received Received
  1040-P OUTCOME OF PATIENTS AGED OVER 60 WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH ABVD Stamatoullas Aspasia Giulia Received Received
  1041-P EVALUATION OF THE PROGNOSTIC ROLE OF TISSUE ASSOCIATED MACROPHAGES (TAM) IN HODGKIN LYMPHOMA AND CORRELATION WITH EARLY FDG-PET ASSESSMENT. Fabbri Alberto Received Received
  1045-P PET-ADAPTED TREATMENT MODIFICATION IN EARLY STAGE HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS Sickinger Marie Therese Received Received
  1049-P ABVD IN TREATMENT OF GENERATIVE AGE FEMALES WITH ADVANCED HODGKIN LYMPHOMA – A RISK FACTOR ANALYSIS Andjelic Bosko Luigia Received Received
  1052-P PRELIMINARY RESULTS OF THE TREATMENT OF PATIENTS WITH HODGKIN´S DISEASE FROM INTERMEDIATE RISK GROUP Kriachok Iryna Luigia Received Received
  1055-P POST-TREATMENT RESIDUAL MASSES DETECTED BY COMPUTED TOMOGRAPHY SCAN SIGNIFICANTLY AFFECT THE CLINICAL OUTCOME OF HODGKIN LYMPHOMA PATIENTS WITH NEGATIVE POSITRON EMISSION TOMOGRAPHY SCAN. Magagnoli Massimo Therese Received Received
  1056-P MYC ONCOGENE IS OVEREXPRESSED IN HODGKIN & REED STERNBERG CELLS (HRS) OF CLASSICAL HODGKIN LYMPHOMA AND CORRELATES WITH P53 EXPRESSION AND PROLIFERATION INDEX RASSIDAKIS George Maria Received Received
  1058-P PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH HODGKIN´S LYMPHOMA Julhakyan Hunan Therese Received Received
  1060-P IMPAIRED RHOA FUNCTION LEADS TO DEVELOPMENT OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA Enami Terukazu Therese Received Received
  1063-P EXPRESSION PATTERN AND FUNCTIONAL ROLE OF TOLL-LIKE RECEPTORS IN SPLENIC MARGINAL ZONE LYMPHOMA Fonte Eleonora Luigia Received Received
  1064-P DROPLET DIGITAL PCR (DDPCR) AND REAL-TIME PCR (RQ-PCR): A HEAD TO HEAD COMPARISON FOR MRD DETECTION IN MYELOMA (MM) MANTLE CELL LYMPHOMA (MCL) AND FOLLICULAR LYMPHOMA (FL) drandi Daniela Luigia Received Received
  1066-P HIGH-THROUGHPUT ANALYSIS OF FULL-LENGTH IMMUNOGLOBULIN TRANSCRIPTS BY TEMPLATE-SWITCHING ANCHORED PCR AND MASSIVE PARALLEL SEQUENCING ON THE PACBIO PLATFORM Koning Marvyn Luigia Received Received
  1068-P GERMLINE SMALL NON CODING RNAS, PIWIRNAS, ARE EXPRESSED IN HODGKIN LYMPHOMA: THE ROLE OF PIWIRNA-651 AS PROGNOSTIC FACTOR IN HODGKIN LYMPHOMA. Navarro Alfons Therese Received Received
  1069-P ISOLD: A VALUABLE SCORE TO DISCRIMINATE OCULAR LYMPHOMA FROM INFLAMMATORY DISEASES Costopoulos Myrto Luigia Received Received
  1070-P GENOME-WIDE DNA METHYLATION ANALYSIS REVEALS ACTIVATION OF WNT SIGNALING PATHWAY IN PERIPHERAL T-CELL LYMPHOMA-NOT OTHERWISE SPECIFIED Zhao Xia Roberta Received Received
  1072-P BACH2 SUPPRESSION IN CD4+ T CELLS MODULATES THEIR RESISTANCE TO APOPTOSIS DEMONSTRATING ITS FUNCTION AS A TUMOR SUPPRESSOR GENE Dang Chi Vu Received Received
  1073-P SUBMICROSCOPIC GENOMIC REARRANGEMENTS CHANGE GENE EXPRESSION IN T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA Izykowska Katarzyna Therese Received Received
  1077-P MIR-150 REGULATES IL-22-CCL20-CCR6 AUTOCRINE PATHWAY IN METASTATIC CUTANEOUS T- CELL LYMPHOMA Teshima Kazuaki Vu Received Received
  1078-P IN VITRO AND IN VIVO EFFECT OF ATO/IFN/AZT FOR ADULT T CELL LEUKEMIA/LYMPHOMA Yoshimitsu Makoto Vu Received Received
  1081-P BONE MARROW INVOLVEMENT AT DIAGNOSIS IS A POOR PROGNOSTIC FACTOR IN YOUNG PATIENTS WITH UNTREATED HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: SUB-ANALYSIS OF THE PHASE III RANDOMIZED FIL-DLCL04 TRIAL Chiappella Annalisa Vu Received Received
  1082-P VITAMIN D DEFICIENCY (VDD) IMPAIRS RITUXIMAB-MEDIATED CELLULAR CYTOTOXICITY AND OUTCOME OF DLBCL PATIENTS TREATED WITH, BUT NOT WITHOUT RITUXIMAB (R) Pfreundschuh Michael Vu Received Received
  1083-P COMBINING SEVERAL MOLECULAR ABNORMALITIES IN IDENTIFICATION OF HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA IMPROVES RISK-STRATIFICATION Fiskvik Idun Therese Received Received
  1084-P DEFINING ACCURACY AND SENSITIVITY OF T-CELL RECEPTOR REPERTOIRE PROFILING FOR MONITORING RECURRENT/PERSISTENT DISEASE IN PATIENTS WITH MATURE T-CELL NEOPLASMS Sanders Catherine Therese Received Received
  1086-P ABNORMAL IMMUNOPHENOTYPE IS OF GREAT VALUE IN THE DIAGNOSIS OF AGGRESSIVE NATURAL KILLER CELL LEUKEMIA Qiu Zhi-Yuan Maria Received Received
  1087-P CNS PROPHYLAXIS IN PATIENTS WITH DLBCL, ARE WE TREATING OURSELVES? A RESPONSE TO THE RECENT BCSH GUIDELINE. griffin Morag Therese Received Received
  1088-P MONOCLONAL AND POLYCLONAL GAMMOPATHY MEASURED BY SERUM FREE LIGHT CHAIN AND IMMUNOFIXATION SUBDIVIDE THE CLINICAL OUTCOMES OF DIFFUSE LARGE B-CELL LYMPHOMA ACCORDING TO MOLECULAR CLASSIFICATION Kim Yu Ri Received Received
  1091-P THE ROLE OF IMAGE GUIDED CORE BIOPSY IN THE DIAGNOSIS OF HAEMATOLOGICAL MALIGNANCY Bailey Katharine Vu Received Received
  1092-P CLINICAL OUTCOME AND PROGNOSIS IN PATIENTS WITH PRIMARY SINONASAL TRACT DIFFUSE LARGE B CELL LYMPHOMA TREATED WITH R-CHOP CHEMOTHERAPY: MULTICENTER RETROSPECTIVE ANALYSIS Lee Gyeong-Won Vu Received Received
  1095-P IDENTIFYING MALIGNANT LYMPH NODES BY NANOPARTICLE MODELLING AND SIMULATIONS: A PRELIMINARY INVESTIGATION De Tullio Giacoma Received Received
  1097-P SERUM LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR (IL2-R), INTERLEUKIN-6 (IL-6) AND TUMOUR NECROSIS FACTOR (TNF) CORRELATE WITH ADVERSE CLINICAL FEATURES AND POOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA dlouhy Ivan Giacoma Received Received
  1099-P ASSOCIATION OF EPSTEIN-BARR VIRUS WITH REGRESSION AFTER WITHDRAWAL OF METHOTREXATE AND PROGRESSION OF IATROGENIC IMMUNODEFICIENCY-ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN AUTOIMMUNE DISEASE Fujimoto Katsuya Ri Received Received
  1101-P DEVELOPMENT OF AN ALPHA/BETA T- CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION PROTOCOL FROM MATCHED RELATED AND UNRELATED DONOR GRAFTS IN PATIENTS WITH POOR RISK LEUKEMIA de Witte Moniek Received Received
  1102-P AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS AND PLATELET-RICH PLASMA ENHANCED RECONSTRUCTION OF THE MAXILLOFACIAL BONY DEFECTS Saad Abdelhamid Alaa Received Received
  1103-P EPSTEIN-BARR VIRUS INFECTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE ROLE OF CYTOMEGALOVIRUS Liu Qifa Alaa Received Received
  1104-P INTENSIFIED CONDITIONING REGIMEN WITH HIGH-DOSE ETOPOSIDE HEMATOPOIETIC STEM CELL TRANSPLANTATION YIELDED PROMISING SURVIVAL FOR HIGH-RISK AND REFRACTORY/RELAPSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA ZHOU Hongsheng Moniek Received Received
  1106-P AUTOLOGOUS OR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH HIGH-RISK AGGRESSIVE LYMPHOMAS: RETROSPECTIVE ANALYSIS IN A SINGLE CENTER IN KOREA Yoon Jae-Ho Moniek Received Received
  1108-P BEEAM (BENDAMUSTINE, ETOPOSIDE, ARA-C, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANT IS SAFE AND EFFECTIVE IN AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: A PHASE II MULTICENTER STUDY Visani G Alaa Received Received
  1109-P USE OF AZATHIOPRINE FOR GRAFT-VERSUS-HOST DISEASE IS THE MAJOR RISK FOR DEVELOPMENT OF SECONDARY PRIMARY MALIGNANCIES AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION Chien Sheng Hsuan Received Received
  1112-P OUTCOME OF PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA RELAPSED AFTER RELATED AND UNRELATED STEM CELL TRANSPLATATION. SINGLE CENTER EXPERIENCE. Steinerova Katerina Moniek Received Received
  1113-P UNRELATED BONE MARROW TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING REGIMEN FOR ELDERLY PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA, FEASIBILITY STUDY WITH TWO-YEAR FOLLOW UP DATA Choi Ilseung Moniek Received Received
  1114-P BIOSIMILAR VERSUS ORIGINATOR G-CSF FOR AUTOLOGOUS STEM CELL MOBILIZATION IN HEMATOLOGIC PATIENTS. AN EXPERIENCE FROM THE PHARMACOVIGILANCE GROUP OF "RETE EMATOLOGICA LOMBARDA" (FARMAREL) PELIZZARI Anna Received Received
  1116-P SEQUENTIAL CHEMOTHERAPY FOLLOWED BY REDUCED INTENSITY CONDITIONING AND ALLOGENEIC HSCT FOR HIGH RISK AML PATIENTS IN FIRST COMPLETE REMISSION: A PROSPECTIVE PILOT STUDY MICHALLET Mauricette Maria Received Received
  1117-P "REAL LIFE" USE OF PLERIXAFOR: A MULTICENTER NORTH EAST ITALY EXPERIENCE Lessi Federica Maria Received Received
  1118-P TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) WITH RITUXIMAB AND NILOTINIB, FIRST RESULTS OF ONGOING CLINICAL TRIAL. VAN DER WAGEN Received Received
  1119-P INCREASED RISK OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN LOW BODY MASS INDEX PATIENTS UNDERGOING HAPLOIDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION chen Yao Maria Received Received
  1123-P (90)Y IBRITUMOMAB TIUXETAN (ZEVALIN) FOLLOWED BY BEAM (Z-BEAM) AND AUTOLOGOUS TRANSPLANT (ASCT) IN POOR PROGNOSIS RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA (NHL): A SINGLE INSTITUTION EXPERIENCE BOTTO Barbara Maria Received Received
  1125-P PLERIXAFOR (MOZOBIL) FOR AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (ASCT) IN HARD TO MOBILIZE NHL AND HL PATIENTS: A PHASE IIB STUDY Nagler Arnon Maria Received Received
  1126-P COMPARISON OF UNRELATED CORD BLOOD WITH BONE MARROW AS A STEM CELL SOURCE FOR MYELOABLATIVE CONDITIONING TRANSPLANTATION IN PATIENTS WITH PEDIATRIC ACUTE LEUKEMIA: A RETROSPECTIVE COHORT STUDY Arakawa Yuki Hsuan Received Received
  1127-P AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: CONTRIBUTION OF NEW PHARMACOLOGICAL HAEMATOPOIESIS SUPPORT Fominykh Mikhail Maria Received Received
  1128-P ANTI-THYMOCYTE GLOBULIN (ATG) COULD IMPROVE THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AGGRESSIVE T CELL TUMORS JUAN Yang Maria Received Received
  1132-P FIRST FRENCH EXPERIENCES OF TOTAL BODY IRRADIATION USING HELICAL TOMOTHERAPY Sun Roger WAGEN Received Received
  1134-P THE ??-DNTS IN LYMPH NODES, BONE MARROW AND PERIPHERAL BLOOD OF LYMPHOMA PATIENTS: POTENTIAL PROGNOSTIC FACTOR OF CLINICAL OUTCOME. De Tullio Giacoma Received Received
  1137-P GENERATION OF MULTIVIRUS-SPECIFIC T CELLS BY A SINGLE STIMULATION OF PBMCS WITH A PEPTIDE MIXTURE UTILIZING SERUM-FREE MEDIUM Fujita Yuriko Hsuan Received Received
  1138-P GENETIC CORRECTION OF DIFFERENTLY MOBILIZED HEMATOPOIETIC STEM CELLS FROM PATIENTS WITH THALASSEMIA AND ENGRAFTMENT KINETICS AFTER XENOTRANSPLANTATION YANNAKI Evangelia Giacoma Received Received
  1139-P NEXT-GENERATION DENDRITIC CELL VACCINATION AS POSTREMISSION THERAPY FOR AML PATIENTS WITH A NON-FAVORABLE RISK PROFILE Lichtenegger Felix Giacoma Received Received
  1140-P FUNCTIONAL EVALUATION OF T-CELLS GENERATED FROM WT1-TCR TRANSDUCED HUMAN HEMATOPOIETIC STEM CELLS USING THE OP9-DL1 COCULTURE SYSTEM. KERRE Tessa Hsuan Received Received
  1141-P OPTIMIZING TUMOR-REACTIVE SINGLE-CHAIN T CELL RECEPTORS FOR ADOPTIVE T CELL TRANSFER Hauptrock Beate Giacoma Received Received
  1142-P COMBINING ADOPTIVE TCR IMMUNOTHERAPY AND ARGININE DEPLETION IN OSTEOSARCOMA XENOGRAFT MODEL Echchannaoui Hakim Giacoma Received Received
  1143-P HDAC6 INHIBITION AUGMENTS THE EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES BY UP-REGULATING CD20 LEVEL IN MALIGNANT B-CELLS Bobrowicz Malgorzata Giacoma Received Received
  1144-P ADOPTIVE CIK CELLS IN PATIENTS WITH LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION li Qing Received Received
  1145-P CYTOMEGALOVIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES RESTRICTED TO HLA-A2 OR HLA-A24 CAN BE EFFICIENTLY GENERATED BY USING GENE-ENGINEERED ARTIFICIAL ANTIGEN-PRESENTING CELLS Ogasawara Masahiro Received Received
  1146-P DESIGNING TCR SPECIFIC FOR HUMAN MDM2 TUMOR-ASSOCIATED ANTIGEN FOR ADOPTIVE IMMUNOTHERAPY AGAINST MELANOMA AND MULTIPLE MYELOMA Amann Eva Giacoma Received Received
  1147-P AN EFFICIENT AND COST EFFECTIVE METHOD FOR THE GENERATION OF CLINICALLY RELEVANT NUMBERS OF MYELOID CORD BLOOD-DERIVED DENDRITIC CELLS BY EMPLOYING CLINICALLY APPROVED AGENTS Kaloyannidis Panayotis WAGEN Received Received
  1148-P HYPOMETHYLATING AGENT AZACITIDINE INDUCES FOXP3 NEGATIVE HLA-G EXPRESSING IMMUNOREGULATORY T CELLS. Stamou Panagiota Giacoma Received Received
  1149-P IMMUNOPHENOTYPIC PROFILE AND FUNCTIONAL CHARACTERISTICS OF NK CELLS EXPANDED FROM CYTOMEGALOVIRUS SEROPOSITIVE AND SERONEGATIVE DONORS: IMPLICATIONS FOR NEW STRATEGIES OF ADOPTIVE CELLULAR THERAPIES Peragine Nadia Giacoma Received Received
  1150-P GENERATION OF PATIENT-INDIVIDUALIZED AML-REACTIVE DONOR CD8+ T CELLS UNDER GMP-COMPLIANT CONDITIONS FOR ADOPTIVE TRANSFER IN LEUKEMIA PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION Chung-Ueck Boidinh WAGEN Received Received
  1151-P LOW-DOSE BORTEZOMIB SENSITIZES MULTIPLE MEYLOMA TO GAMMA-DELTA T CELLS LYSIS Niu Chao Hsuan Received Received
  1152-P HUMAN MONOCYTE-DERIVED DENDRITIC CELLS EXPOSED TO HYPERTHERMIA SHOW A DISTINCT GENE EXPRESSION PROFILE AND SELECTIVE UPREGULATION OF IGFBP-6 Liso Arcangelo Hsuan Received Received
  1153-P ROLE OF LONG PENTRAXIN 3 (PTX3) IN WOUND CLOSURE INDUCED BY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS Cappuzzello Claudia Giacoma Received Received
  1155-P QUANTITATIVE T2* MRI FOR BONE MARROW IRON OVERLOAD ASSESSMENT IN A LARGE COHORT OF THALASSEMIA MAJOR PATIENTS. Meloni Antonella Received Received
  1156-P BONE MINERAL DENSITY IMPROVEMENT IN PATIENTS WITH THALASSEMIA MAJOR ON LONG-TERM CHELATION THERAPY WITH DEFERASIROX Casale Maddalena Giacoma Received Received
  1158-P 18 MONTHS DATA OF A RANDOMIZED CONTROLLED TRIAL OF COMBINED DEFERIPRONE (DFP) AND DEFERASIROX (DFX) VERSUS COMBINED DEFERIPRONE AND DEFEROXAMINE (DFO), IN YOUNG ?-THALASSEMIA MAJOR ADLY Amira Received Received
  1159-P HIGH PREVALENCE, EXTENT AND SEVERITY OF SPINAL DEGENERATIVE CHANGES IN ADULT THALASSAEMIA PATIENTS PRESENTING WITH BACK PAIN SHAH Farrukh Received Received
  1160-P PEDIATRIC THALASSEMIA MAJOR PATIENTS : PROSPECTIVE COMPARISON OF CHELATION TREATMENTS Meloni Antonella Hsuan Received Received
  1161-P TISSUE IRON DEPOSITION AND MARKERS OF GLUCOSE DYSREGULATION IN THALASSEMIA MAJOR Aydinok Yesim Giacoma Received Received
  1162-P PRESENCE OF THE IVS1-6 MUTATED ALLELE PREDISPOSES PATIENTS WITH MAJOR ? THALASSAEMIA TO EXTRAMEDULLARY HAEMATOPOISES Adamidou Despoina Giacoma Received Received
  1163-P BONE MINERALIZATION AND ENDOCRINE DISEASE IN PATIENTS WITH BETA-THALASSEMIA INTERMEDIA (TI). Marcon Alessia Giacoma Received Received
  1164-P INVESTIGATION OF RENAL FUNCTION DISORDERS IN PATIENTS WITH THALASSEMIA AND THEIR RELATION WITH IRON OVERLOAD deveci Burak WAGEN Received Received
  1165-P ASSOCIATION OF OR51B2 SEQUENCE VARIATIONS WITH RESPONSE TO HYDROXYUREA THERAPY IN IRANIAN PATIENTS AFFECTED WITH BETA-THALASSEMIA INTERMEDIA KARIMI Mehran Hsuan Received Received
  1166-P LEFT VENTRICULAR GLOBAL FUNCTION INDEX BY CMR IS MORE STRONGLY ASSOCIATED TO DIFFERENT PATTERNS OF MYOCARDIAL IRON OVERLOAD THAN THE GLOBAL SYSTOLIC FUNCTION Meloni Antonella Hsuan Received Received
  1167-P PROSPECTIVE MRI STUDY IN PEDIATRIC THALASSEMIA MAJOR (TM) PATIENTS IN THE MIOT NETWORK: A TOOL TO STRENGTHEN MEDICAL DECISIONS. Meloni Antonella Hsuan Received Received
  1168-P THE ROLE OF LEFT VENTRICULAR GLOBAL FUNCTION INDEX FOR THE PREDICTION OF CARDIAC COMPLICATIONS IN THALASSEMIA MAJOR Meloni Antonella Hsuan Received Received
  1169-P RIGHT VENTRICULAR WALL MOTION ABNORMALITIES IN PATIENTS WITH THALASSEMIA MAJOR AND INTERMEDIA Meloni Antonella Hsuan Received Received
  1170-P TROPONINE T AS A MARKER OF CARDIAC IMPAIRMENT IN PATIENTS SUFFERING THALASSEMIA Vetro Calogero Hsuan Received Received
  1173-P CLINICAL HETEROGENEITY OF AUTOIMMUNE HEMOLYTIC ANEMIA: A GIMEMA STUDY OF 308 PATIENTS Barcellini Wilma Giacoma Received Received
  1174-P REDUCED 25-OH VITAMIN D LEVELS IN PATIENTS WITH AUTOIMMUNE CITOPENIAS: CORRELATION WITH HAEMATOLOGICAL PARAMETERS AND CLINICAL SEVERITY Fattizzo Bruno Giacoma Received Received
  1176-P SIROLIMUS AS TREATMENT OF STEROID DEPENDENT/RESISTANT AUTOIMMUNE HAEMOLYTIC ANEMIA/PURE RED CELL ANEMIA IN CHILDREN Miano Maurizio Hsuan Received Received
  1177-P ANALYSIS OF CAUSES OF ANAEMIA FOUND IN A GENERAL PRACTICE POPULATION: PREVALENCE AND SURVIVAL Stouten Karlijn Giacoma Received Received
  1178-P RENAL FUNCTIONAL AND STRUCTURAL INTEGRITY IN CHILDREN WITH IRON DEFICIENCY ANEMIA: RESPONSE TO IRON THERAPY El-Farrash Rania Hsuan Received Received
  1179-P MULTIFACTORIAL PATHOGENESIS OF ANEMIA IN PREGNANCY Demikhov Valerii Hsuan Received Received
  1181-P THROMBOEMBOLISM OCCURRED REGARDLESS OF HEMOLYSIS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA– A PROSPECTIVE STUDY OF 464 PATIENTS IN A MULTICENTER CHINESE REGISTRY Zhang Danyu WAGEN Received Received
  1182-P NEW RED BLOOD CELL AUTOMATED PARAMETERS FOR IRON DEFICIENCY SCREENING IN CHRONIC INFLAMMATORY DISEASE Lazarova Elena Giacoma Received Received
  1184-P MICROCYTIC ANAEMIA AND IRON METABOLISM IN ERYTHROPOIETIC PROTOPORPHYRIA spinelli Diana Giacoma Received Received
  1185-P SIGNIFICANT IMPACT OF IRON CHELATION AFTER ALLOGENEIC HEMATOPOETIC STEM CELL TRANSPLANTATION ON DISEASE RECURRENCE: POTENTIAL ANTI-LEUKEMIC ACTIVITY MICHALLET Mauricette Received Received
  1186-P INVESTIGATION ON THE EARLIEST SIGN OF INVASIVE PULMONARY ASPERGILLOSIS (IPA) AND THE ONSET, WITH ROUTINE NON-PYREXIA PHASE CT BASED DIAGNOSTIC STRATEGY, A COHORT STUDY Kyo Kouhei Giacoma Received Received
  1189-P AEROSOLIZED LIPOSOMAL AMPHOTERICIN-B TO PREVENT INVASIVE PULMONARY ASPERGILLOSIS IN ACUTE MYELOID LEUKEMIA. EFFICACY AND COST-EFFECTIVENESS IN REAL-LIFE. Chong Ga-Lai WAGEN Received Received
  1190-P HIGH RISK OF INVASIVE FUNGAL INFECTIONS (IFI) IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS RECEIVING INDUCTION AND SALVAGE CHEMOTHERAPY WITH ITRACONAZOLE PROPHYLAXIS – TIME TO CHANGE GAME PLAN Wong Gee Chuan Received Received
  1191-P A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS OF ANTIFUNGAL TREATMENTS IN ONCO-HEMATOLOGIC PATIENTS Fracchiolla Nicola Chuan Received Received
  1194-P IMPACT OF TOLL-LIKE RECEPTOR 4 POLYMORPHISMS ON INFECTIOUS COMPLICATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA Schnetzke Ulf Giacoma Received Received
  1195-P THE EXPRESSION OF TOLL-LIKE RECEPTORS AND DEVELOPMENT OF SEVERE SEPSIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIAS. Rybka Justyna Giacoma Received Received
  1196-P ANTIBACTERIAL PROPHYLAXIS AND EMERGING RESISTANT STRAINS IMPACT ON EPIDEMIOLOGY AND OUTCOME OF BLOODSTREAM INFECTIONS IN ACUTE LEUKAEMIA: A PROSPECTIVE STUDY BY THE RETE EMATOLOGICA LOMBARDA (REL) Cattaneo Chiara Giacoma Received Received
  1198-P THE INCREASING PROBLEM OF BLOODSTREAM INFECTIONS CAUSED BY MULTI-DRUG RESISTANT BACTERIA IN HEMATOLOGIC AND HSCT PATIENTS. Candoni Anna Chuan Received Received
  1200-P CLOSTRIDIUM DIFFICILE INFECTIONS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY IN CZECH AND SLOVAK REPUBLIC – A RETROSPECTIVE ANALYSIS Palackova Martina WAGEN Received Received
  1202-P A SINGLE-INSTITUTION EXPERIENCE OF PERIPHERAL INSERTED CENTRAL VENOUS CATHETERS IN ONCO-HEMATOLOGIC PATIENTS Fracchiolla Nicola Giacoma Received Received
  1208-P CLINICAL FEATURES, GENETICS AND OUTCOME OF PEDIATRIC PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN KOREA: REPORT OF A NATIONWIDE SURVEY FROM KOREA HISTIOCYTOSIS WORKING PARTY Lee Seong Wook Received Received
  1212-P OXIDANT STATUS IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) AND THE ROLE OF AN ADJUVANT ANTIOXIDANT THERAPY. elhenawy Yasmine Received Received
  1213-P EPIDEMIOLOGY OF INCIDENT IMMUNE THROMBOCYTOPENIA IN FRANCE: A NATIONWIDE POPULATION-BASED STUDY. Moulis Guillaume Wook Received Received
  1214-P RITUXIMAB REVERSED THE INCREASE IN SPLENIC T FOLLICULAR HELPER CELLS DURING IMMUNE THROMBOCYTOPENIA. Audia Sylvain Wook Received Received
  1215-P SUSTAINED RESPONSE AFTER THROMBOPOIETIN RECEPTOR AGONISTS DISCONTINUATION IN 5 PATIENTS AFFECTED BY PRIMARY IMMUNE THROMBOCYTOPENIA Santoro Cristina Wook Received Received
  1216-P NOVEL MUTATIONS AT GPIIB/GPIIIA GENES FROM TURKISH PATIENTS WITH GLANZMANN THROMBASTHENIA SYNDROME Özkan Didem (Torun) Received Received
  1217-P NEXT GENERATION SEQUENCING OF NBEAL2 GENE MUTATIONS IN GRAY PLATELET SYNDROME Ma Edmond (Torun) Received Received
  1218-P IS HIGHER IL-21 LEVEL PREDICTIVE OF RELAPSES IN IMMUNE THROMBOCYTOPENIA AND IS IT ASSOCIATED WITH ACTIVATION OF THE COMPLEMENT SYSTEM? Pamuk Gulsum (Torun) Received Received
  1220-P CLINICO-PATHOLOGIC FEATURES OF COMMON VARIABLE IMMUNODEFICIENCY (CVID) PATIENTS MANIFESTING CYTOPENIAS Srirangam Vinaya (Torun) Received Received
  1221-P PRIMARY VERSUS SECONDARY ITP IN ADULTS ; A COMPARATIVE ANALYSIS OF CLINICAL AND LABORTORY ATTRIBURTES IN NEWLY DIAGNOSED PATIENTS IN AN ASIAN POPULATION. sultan Dr Received Received
  1222-P ROUTINE BONE MARROW EXAMINATIONS MAY NOT BE NECESSARY IN THE EVALUATION OF PATIENTS WITH INMUNE THROMBOCYTOPENIA OLIVERA SUMIRE Pavel Received Received
  1223-P RITUXIMAB SALVAGE THERAPY IN ADULTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: EFFICACY AND SAFETY Reboursiere Emilie WAGEN Received Received
  1224-P INTERNATIONAL ITP REGISTRY WITH FOCUS ON THE ASIA PACIFIC REGION: PRELIMINARY FINDINGS OF EPIDEMIOLOGICAL AND CLINICAL DATA McIntyre Kiara Pavel Received Received
  1225-P CMV INFECTION DOES NOT HAVE AN IMPACT ON BLEEDING MANIFESTATIONS OR PROGNOSIS OF IDIOPATHIC THROMBOCYTOPENIA Ragab Iman Pavel Received Received
  1226-P THE RISK OF CANCER IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): A NATIONWIDE POPULATION-BASED STUDY Hu Ming-Hung Pavel Received Received
  1227-P HELICOBACTER PYLORI INFECTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA. Jimenez-Barcenas Reyes Pavel Received Received
  1229-P CLINICAL ANALYSIS OF EFFECT OF HELICOBACTER PYLORI ERADICATION IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA Hongqiong Fan Received Received
  1236-P THE EFFECT OF MORBID OBESITY ON THROMBIN GENERATION AND SENSITIVITY TO THE ANTICOAGULANT ACTIVATED PROTEIN C IN PREGNANT WOMEN Kevane Barry Pavel Received Received
  1237-P HYPOXIA CONTRIBUTES TO PROCOAGULANT ACTIVITY OF BREAST CANCER CELLS cui Xueyan Pavel Received Received
  1238-P IMPACT OF RECOMBINANT THROMBOMODULIN ON THE OUTCOME OF NEONATES WITH DISSEMINATED INTRAVASCULAR COAGULATION DIFFERS ACCORDING TO APGAR SCORE Yagasaki Hiroshi Pavel Received Received
  1240-P HIGH INCINDENE OF CEREBRAL LEISIONS IN ADULT PATIENTS WITH BETA-THALASSEMIA MAJOR Stark Pinhas Received Received
  1241-P PLATELET THROMBUS FORMATION UNDER FLOW CONDITION IS INCREASED IN MYELOPROLIFERATIVE NEOPLASMS (MPNS) Tessarolo Serena Pavel Received Received
  1243-P INCREASED FIBRINOGEN LEVELS AND TESTOSTERONE DEFICIENCY HAVE AN ADDITIVE DETRIMENTAL EFFECT ON CAROTID WALL THICKNESS IN ESSENTIAL HYPERTENSIVE PATIENTS Pallantza Zoi Pina Received Received
  1244-P FUNCTIONAL EVALUATION OF TISSUE FACTOR IN FLOW-DEPENDENT THROMBUS FORMATION ON IMMOBILIZED VON WILLEBRAND FACTOR Sugimoto Mitsuhiko Received Received
  1245-P CLINICAL SIGNIFICANCE OF THE NEUTROPHIL-LYMPHOCYTE RATIO IN VENOUS THROMBOEMBOLISM PATIENTS WITH LUNG CANCER Lee Gyeong-Won Pavel Received Received
  1246-P PATTERNS OF DIFFERING THROMBIN GENERATION AND SENSITIVITY TO THE ANTICOAGULANT ACTIVATED PROTEIN C IN PATIENTS WITH MYELOMA AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE. Crowley Maeve P Received Received
  1248-P HAEMATOLOGICAL MORBIDITY IN OBSTETRIC PATIENTS WITH CARDIAC DISEASE Kevane Barry Pavel Received Received
  1249-P PREVALENCE OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A DANISH FOLLOW-UP STUDY Severinsen Marianne Tang Received Received
  1251-P A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE INCIDENCE OF MAJOR BLEEDING IN OVER 1000 PATIENTS COMMENCED ON RIVAROXABAN FOR NON-VALVULAR ATRIAL FIBRILLATION AND VENOUS THROMBOEMBOLISM Jenkins Stephen P Received Received
  1253-P MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PATIENTS WITH ACUTE UNPROVOKED DEEP VEIN THROMBOSIS AND DURING THE COURSE OF ONE YEAR THALER Johannes Received Received
  1254-P DEVELOPMENT OF A PHARMACOGENETIC-BASED WARFARIN DOSING ALGORITHM IN BRAZILIAN PATIENTS Santos Paulo Received Received
  1255-P CURRENT MANAGEMENT AND OUTCOMES OF VENOUS THROMBOEMBOLISM IN AUSTRALIA: INITIAL RESULTS FROM THE VENOUS THROMBOEMBOLISM COHORT STUDY Aoki Naomi Tang Received Received
  1256-P IN-VIVO REVERSAL OF THE ANTICOAGULANT EFFECT OF APIXABAN WITH 4-FACTOR PROTHROMBIN COMPLEX CONCENTRATE Cheung Yuk Wah Received Received
  1257-P EFFICACY OF REPEAT DUPLEX ULTRASOUND IN PATIENTS WITH SUSPECTED DEEP VENOUS THROMBOSIS Scholtes Brian Tang Received Received
  1258-P SPANISH REGISTRY OF THROMBOEMBOLIC DISEASE (TD) RELATED WITH HORMONAL THERAPY, PREGNANCY, OBSTETRICS COMPLICATIONS OR ASSISTED REPRODUCTIVE TECHNIQUES IN WOMEN (ARP): RESULTS OF THE TEAM PROJECT santamaria Amparo Received Received
  1259-P RETROSPECTIVE AUDIT OF INCIDENCE OF PICC LINE RELATED DEEP VEIN THROMBOSIS IN HAEM-ONCOLOGY PATIENTS Sriskandarajah Priya Received Received
  1260-P THREE YEAR MORTALITY ASSOCIATED WITH VENOUS THROMBOEMBOLISM (VTE): COMPARISON OF HOSPITAL ACQUIRED, COMMUNITY ACQUIRED AND INCIDENTAL FINDINGS Rowswell Huw Tang Received Received
  1261-P INFLAMMATORY RESPONSE AMONG PATIENTS WITH SUSPECTED VENOUS THROMBOEMBOLISM Mosevoll Knut Received Received
  1262-P REDUCTIONS IN VENOUS THROMBOEBOLISM EVENTS, ASSOCIATED WITH RADIOLOGICAL DATA PROVIDING REAL-TIME FEEDBACK TO CLINICIANS ABOUT HOSPITAL ACQUIRED THROMBOSIS, GIVEN INADEQUATE PREVENTATIVE MEASURES Rowswell Huw Anders Received Received
  1264-P LONG-TERM OUTCOME OF NON-CENTRAL-VENOUS-LINE-RELATED DEEP VEIN THROMBOSES LOCATED AT LOWER LIMBS IN CHILDREN Pergantou Helen Anders Received Received
  1265-P MORTALITY AND INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES AND RELATION TO LABORATORY BIOMARKERS: AN UPDATE OF A SINGLE CENTER STUDY Elmoamly Shereef Received Received
  1266-P GENETIC AND ACQUIRED PREDICTORS OF POSTTHROMBOTIC SYNDROME IN YOUNG PATIENTS WITH DVT IN THE NORTH-WEST REGION OF RUSSIA Demyanenko Anna Received Received
  1267-P EFFICACY, SAFETY AND CLINICAL MANAGEMENT OF THE NEW GENERATION ORAL ANTICOAGULANTS (NOAS) IN THE CLINICAL PRACTICE: "THE REAL LIFE COHORT STUDY". OLIVERA SUMIRE Pavel Received Received
  1268-P COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Marchetti Monia Anders Received Received
  1269-P ECONOMIC VALUE CREATED BY ADDING RITUXIMAB TO CHEMOTHERAPY IN THE UNITED STATES FROM 1998-2013 Reyes Carolina Anders Received Received
  1271-P IS OBINUTUZUMAB COST-EFFECTIVE FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES? Reyes Carolina Wah Received Received
  1272-P HOME CARE MANAGEMENT FOR HEMATOLOGICAL PATIENTS: RESULTS OF A SURVEY CONDUCTED ON A REGIONAL SCALE BY THE R.E.D.E.R. NETWORK Alfieri Pierluigi Anders Received Received
  1273-P SENSITIVITY COST ANALYSIS OF TYROSINE KINASE INHIBITORS IN PHARMACOECONOMIC MODELING OF CML TREATMENT SHUVAEV Vasily Wah Received Received
  1274-P DIRECT COST ANALYSIS ABOUT THE THREE CHELATORS FOR THE TREATMENT OF THALASSEMIA PATIENTS WITH CHRONIC IRON OVERLOAD: AN ITALIAN PERSPECTIVE FROM THE MIOT NETWORK Meloni Antonella Pavel Received Received
  1276-P PATTERN OF ADVERSE DRUG REACTIONS IN ONCO-HEMATOLOGIC PATIENTS: RESULTS FROM THE ITALIAN PHARMACOVIGILANCE PROJECT NAMED "FARMAREL" Fracchiolla Nicola Wah Received Received
  1277-P PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL Haycox Alan Anders Received Received
  1279-P PREVENTABILITY ASSESSMENT OF ADVERSE DRUG REACTIONS IN ONCOHEMATOLOGIC PATIENTS: HEMATOLOGY CLINICAL JUDGMENT COMPARED TO SCHUMOCK AND THORNTON EXPLICIT CRITERIA Fracchiolla Nicola Wah Received Received
  1280-P COMPARATIVE ANALYSIS OF ADVERSE REACTIONS ARISING FROM THE ADMINISTRATION OF CONVENTIONAL CYTOTOXIC DRUGS AND RECENT TARGETED AGENTS, ALONE OR IN ASSOCIATION, IN ONCOHEMATOLOGIC PATIENTS Fracchiolla Nicola Anders Received Received
  1281-P SOCIETAL ECONOMIC BURDEN OF IRON DEFICIENCY INDUCED FATIGUE Blank Patricia R. Received Received
  1282-P WILL SUBSTITUTION OF TKI GENERIC BRING THE CML TREATMENT FUTURE TO THE PAST? PHARMACOECONOMIC MODELING OF CML TREATMENT WITH OWN GENERIC USE EXPERIENCE. SHUVAEV Vasily R. Received Received
  2444-LB ACCELERATION OF BCR-ABL+ LEUKEMIA INDUCED BY DELETION OF JAK2 Eva Grundschober Received Received
  2446-LB IRON-INDUCED EPIGENETIC ABNORMALITY OF MOUSE BONE MARROW THROUGH ABERRANT ACTIVATION OF ACONITASE AND ISOCITRATE DEHYDROGENASE WITHOUT GENE MUTATION: ANALYSIS BY HIGH THROUGHPUT SEQUENCER AND GC-MS. Masayo Yamamoto Received Received
  2448-LB RESPONSE TO LISINOPRIL IN PATIENTS WITH SICKLE CELL ANEMIA AND PROTEINURIA Aamer Aleem Received Received
  2450-LB ICARS: ENGINEERED SAFETY FOR T CELL IMMUNOTHERAPY Raffaella Pippa Received Received
  2451-LB PRETREATMENT D-2-HYDROXYGLUTARATE SERUM LEVELS PREDICT OUTCOME IN IDH1-MUTATED ACUTE MYELOID LEUKEMIA Christoph Heilig Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon - Fri 8:15 - 15:00
09:28
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN HEMATOLOGY ASSOCIATION

19th Congress of EHA

 

12 - 15 June 2014 Milan
HELP LINE
Manage Orders
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 12/06/2014 TO 15/06/2015
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                  
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 29/05/2014
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster







PosterSessionOnline
Logo Draft
 
Logo Cert